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Introduction: Smokers with mental illness (MI) are disproportionately affected by negative 
health outcomes. Electronic nicotine delivery systems (ENDS) may represent a harm reduction 
tool for those who reduce and/or replace their cigarettes with ENDS. Little previous research has 
examined how smokers with MI respond to ENDS. This analysis aimed to address this research 
gap using secondary data from a randomized controlled trial of ENDS varying in nicotine 
delivery among smokers with and without current MI. The aims were to test 1) the effects of MI 
status, condition, and time on changes in smoking behavior and negative mood and stress 
measures, 2) whether changes in negative mood and stress mediate condition-related effects on 
smoking, and 3) whether this mediation was moderated by MI status.  
Methods: Smokers (n=520) interested in reduction but not cessation were randomized to receive 
either a non-nicotine-containing plastic cigarette substitute (CIG SUB) or ENDS differing in 
liquid nicotine concentration (0, 8, or 36 mg/ml) for 24 weeks. MI status was assessed at 
baseline. Smoking behavior (cigarettes per day; CPD) and negative mood (depression, 
psychological distress) and perceived stress measures were assessed at week 0, 4, 8, 16, and 24. 
Conditions were collapsed by nicotine-containing status (CIG SUB/0 mg/ml vs. 8/36 mg/ml), 
and participants were categorized by MI status (yes, no). Linear mixed models and mediation 
models were used. Sensitivity analyses included covariate adjustment.  
Results: CPD reduction was significantly greater among smokers without MI at week 16 and 24 
for the unadjusted analysis only. Nicotine conditions were associated with significantly greater 
CPD reduction at all time points, and both condition groupings resulted in significant CPD 
reduction relative to baseline. Significantly greater depressive symptoms were observed for non-






nicotine conditions at week 24. With covariate adjustment, negative mood measures were 
significantly higher at later study time points for those with MI. Perceived stress differed by MI 
status but not condition grouping. Changes in negative mood and stress did not mediate CPD 
reduction, but direct effects of condition as well as changes in negative mood on CPD reduction 
were observed.  
Conclusions: Our findings indicate that smokers with MI may experience greater difficulty 
reducing CPD, but nicotine conditions had similar effectiveness in reducing CPD relative to non-
nicotine conditions among smokers with and without MI. Smokers with MI reported increased 
negative mood at some time points, but changes in negative mood and stress did not explain the 
relationship between condition and CPD reduction. Results highlight the need for mood 
management during smoking reduction and cessation efforts for smokers with MI and support 








Table of Contents 
Acknowledgments........................................................................................................................... 2 
Abstract........................................................................................................................................... 3 
List of Figures................................................................................................................................. 8 
List of Tables.................................................................................................................................. 9 
List of Abbreviations.................................................................................................................... 10 
Introduction ................................................................................................................................... 11 
Overview and Motivation for Study ......................................................................................... 11 
Cigarette Smoking and MI Status ............................................................................................. 12 
Mechanisms Underlying the Relationship Between Mental Health and Smoking ................... 15 
     Pharmacology of nicotine .................................................................................................... 16 
     Development of tolerance and dependence. ........................................................................ 17 
     Bidirectional relationship between smoking and MI ........................................................... 19 
     Self-medication hypothesis .................................................................................................. 20 
     Social and environmental factors ......................................................................................... 23 
     Summary.............................................................................................................................. 24 
Smoking Cessation/Harm Reduction Challenges among Smokers with Mental Illness .......... 24 
Smoking Cessation/Harm Reduction Treatment Approaches for Those with Mental Illness.. 28 
    Effectiveness of available treatments in smokers with mental illness .................................. 31 
ENDS Use, Nicotine Delivery, and Use Among Individuals with Mental Illness................... 33 
     What are ENDS?.................................................................................................................. 33 
Nicotine Delivery from ENDS................................................................................................. 35 
ENDS for Smoking Cessation and Reduction.......................................................................... 38 
     Use behaviors and perceptions of ENDS among individuals with mental illness............... 40 
ENDS and Smoking Cessation and Reduction for Smokers with Mental Illness.................... 42 
Statement of the Problem .......................................................................................................... 44 
The Present Study Aims and Hypotheses ................................................................................. 44 
Methods......................................................................................................................................... 49 
Trial Design .............................................................................................................................. 49 
Participants ................................................................................................................................ 50 






Study Products.......................................................................................................................... 53 
Measures................................................................................................................................... 54 
    Main outcome measures....................................................................................................... 54 
        Depressive symptoms........................................................................................................... 55 
        Psychological distress........................................................................................................... 55 
        Perceived stress..................................................................................................................... 56 
        Cigarettes per day................................................................................................................. 56 
        Covariates............................................................................................................................. 56 
        Demographic variables......................................................................................................... 56 
        Baseline characteristics......................................................................................................... 57 
        Tobacco dependence-related measures................................................................................. 58 
Data Analysis ............................................................................................................................ 59 
         Data preparation................................................................................................................... 59 
         Analyses............................................................................................................................... 61 
 Aim 1 Analysis................................................................................................................. 61 
            Aim 2 Analysis................................................................................................................. 62 
            Aim 3 Analysis................................................................................................................. 62 
            Sensitivity Analysis.......................................................................................................... 64 
            Aim 1 and 2 Power Analysis............................................................................................ 65 
Results.......................................................................................................................................... 66 
        Current sample..................................................................................................................... 66 
       Differences by MI status....................................................................................................... 70 
       Aim 1 and 2........................................................................................................................... 73 
            Cigarettes per day............................................................................................................. 76 
            Cigarettes per day: Sensitivity analysis............................................................................ 78 
             Depressive symptoms...................................................................................................... 81 
             Depressive symptoms: Sensitivity analysis..................................................................... 82 
             Psychological distress...................................................................................................... 84 






            Perceived stress................................................................................................................. 87 
            Perceived stress: Sensitivity analysis................................................................................ 87 
      Aim 3...................................................................................................................................... 88 
             Negative mood and stress................................................................................................ 88 
             Negative mood and stress: Sensitivity analysis............................................................... 89 
             Negative mood................................................................................................................. 90 
             Negative mood: Sensitivity analysis................................................................................ 91 
             Depressive symptoms...................................................................................................... 92 
             Depressive symptoms: Sensitivity analysis..................................................................... 93 
             Psychological distress...................................................................................................... 94 
             Psychological distress: Sensitivity analysis..................................................................... 95 
             Perceived stress................................................................................................................ 96 
             Perceived stress: Sensitivity analysis............................................................................... 97 
Discussion ..................................................................................................................................... 98 
Aim 1: Cigarettes per day.................................................................................................99 
Aim 2: Negative mood and stress.................................................................................. 103 




References ................................................................................................................................... 118 








List of Figures 
Figure 1: Hypothesized results for H1b........................................................................................ 46 
Figure 2: Hypothesized results for H2.......................................................................................... 47 
Figure 3: Study design schematic by week and condition............................................................ 52 
Figure 4: Study products............................................................................................................... 53 
Figure 5: Planned mediation model.............................................................................................. 63 
Figure 6: Planned moderated mediation model............................................................................ 64 
Figure 7: Cigarettes per day over time by current mental illness status....................................... 77 
Figure 8: Cigarettes per day over time by non-nicotine and nicotine conditions......................... 78 
Figure 9: Cigarettes per day over time by current MI status with covariate adjustment.............. 79 
Figure 10: Cigarettes per day over time by condition grouping................................................... 81 
Figure 11: CES-D scores over time by condition grouping.......................................................... 82 
Figure 12: CES-D scores over time by condition grouping adjusted for covariates.................... 83 
Figure 13: Kessler-6 scores over time by condition grouping...................................................... 85 
Figure 14: Kessler-6 scores over time by current MI status adjusted for covariates.................... 86 
Figure 15: Simple mediation model negative mood and stress unadjusted for covariates........... 89 
Figure 16: Simple mediation model negative mood and stress adjusted for covariates............... 90 
Figure 17: Simple mediation model negative mood unadjusted for covariates............................ 91 
Figure 18: Simple mediation model negative mood adjusted for covariates................................ 92 
Figure 19: Simple mediation model depressive symptoms unadjusted for covariates................. 93 
Figure 20: Simple mediation model depressive symptoms adjusted for covariates..................... 94 
Figure 21: Simple mediation model psychological distress unadjusted for covariates................ 95 
Figure 22: Simple mediation model psychological distress adjusted for covariates.................... 96 
Figure 23: Simple mediation model perceived stress unadjusted for covariates.......................... 97 







List of Tables 
Table 1: Nicotine boost from study products after 10 puffs by user experience.......................... 37 
Table 2: Current MI among participants previously reporting lifetime MI.................................. 54 
Table 3: Observed power for outcomes across week 0 and week 24........................................... 66 
Table 4: Missed visits by condition grouping............................................................................... 67 
Table 5: Percentage of missing data on mood and stress measures across time points................ 67 
Table 6: Baseline characteristics by condition grouping.............................................................. 68 
Table 7: Current mental illness diagnoses by condition grouping................................................ 70 
Table 8: Baseline characteristics by current mental illness status................................................ 71 
Table 9: Missed visits by current MI status as recorded at each time point................................. 73 
Table 10: Statistical results summary for Aim 1 and 2 linear mixed models............................... 74 

















List of Abbreviations 
CES-D Center for Epidemiologic Studies Depression Scale  
CIG SUB Cigarette substitute 
CO Carbon monoxide 
CPD Cigarettes per day 
EM Expectation maximization 
ENDS Electronic nicotine delivery system(s) 
FDA US Food and Drug Administration  
MI Mental illness 
nAChR Nicotinic acetylcholine receptors 
PSCDI Penn State Cigarette Dependence Index 
PSS Perceived Stress Scale 
RCT Randomized controlled trial 
REML Restricted Maximum Likelihood 
RR Risk ratio 
SAMHSA Substance Abuse and Mental Health Services Administration 
SMI Serious mental illness 
US  United States 









Overview and Motivation for Study  
Smoking causes 480,000 deaths annually in the United States (US; Centers for Disease 
Control and Prevention, 2014). Smoking-related diseases and death are particularly prominent 
among populations with mental illness (MI). Relative to smokers without MI, smokers with MI 
are at an increased risk of suffering from smoking-related cancers and cardiovascular disease 
(Callaghan et al., 2014). For example, approximately 53% of deaths among individuals with 
schizophrenia, 48% of deaths among individuals with bipolar disorder, and 50% of deaths among 
individuals with depressive disorder are attributed to tobacco use (Callaghan et al., 2014). The 
smoking-related death rates among individuals with MI may be attributed partially to the 
smoking prevalence and intensity among these populations.  
Relative to smoking rates among individuals without MI (15.5%), current smoking rates 
among individuals with MI are much higher for individuals with lifetime MI (33.4%) and 
individuals with past-year MI (39.0%; Smith et al., 2014). Moreover, 40% of all cigarettes 
produced in the US are consumed by smokers with MI (Substance Abuse and Mental Health 
Services Administration; SAMHSA, 2013). Cessation rates among smokers with MI are lower 
than rates observed among individuals without MI; for example, smokers with past-month MI 
reported quitting at significantly lower rates relative to smokers without MI (30.5% vs. 42.5%), 
with cessation rates observed to be as low as 22.0% for individuals with dysthymia (Lasser et al., 
2000) for example.  
Potential barriers for successful smoking cessation among smokers with MI include 






al., 2016), limited access to cessation resources (SAMHSA, 2013) as well as nicotine 
dependence-related factors (Pomerleau et al., 2005). Innovative and timely approaches to 
promote cessation as well as harm reduction for those who experience greater barriers are needed 
to address these MI and tobacco-related disparities. One such tool may be electronic nicotine 
delivery systems (ENDS). While not harmless, ENDS represent a potential means to deliver 
nicotine without many of the harmful constituents associated with combusted tobacco use 
(National Academies of Sciences, 2018). Systematic study of ENDS use among individuals with 
mental health conditions is limited, but results among general populations indicate that these 
novel tobacco products may hold promise for some groups of smokers (Gentry et al., 2019). 
Cigarette Smoking and MI Status 
Significant strides have been made in tobacco prevention efforts, as highlighted by 
nationally representative survey data collected between 2004 to 2011 that suggest a decrease in 
smoking rates among individuals without MI from 19.2% to 16.5% during that time (Cook et al., 
2014). In contrast, during the same time period, smoking rates among those with any MI only 
decreased from 25.3% to 24.9% (Cook et al., 2014). The term MI describes a health condition 
during which the affected individual exhibits changes in cognitive, emotional, and/or behavioral 
processes that in turn can influence the affected individual’s functioning in important areas of 
their life negatively, including work and social functioning (American Psychiatric Association; 
APA, 2018). The classification category of any MI may include any mental, emotional, or 
behavioral disorder regardless of the mild or severe nature of the impairment associated with the 
disorder (National Institute of Mental Health; NIMH, 2019a). Substance use disorders are 
considered to be MI as well (NIMH, 2021). The classification of severe MI is limited to illnesses 






causing impairment in at least one area of life (NIMH, 2019a). Severe MI includes 
schizophrenia, bipolar disorder, major depression with symptoms of psychosis, or psychotic 
disorder but can involve anxiety, personality disorders, and eating disorders if the affected 
individual suffers from severe MI-related impairment due to their disorder (Evans et al., 2016). 
Today, smoking prevalence rates among individuals with MI remain disproportionately 
high. As of 2018, 16.3% of individuals without MI reported current (past 30-day) cigarette 
smoking (SAMHSA, 2019). In comparison, current smoking rates among those with any past-
year MI was 28.1% (SAMHSA, 2019). Individuals suffering from multiple MIs have even higher 
smoking rates (Lasser et al., 2000). Particularly high prevalence of smoking is observed among 
individuals with severe MI. Among individuals with past-year SMI, 37.2% were current smokers 
(SAMHSA, 2019) with some of the highest rates of use observed among individuals with 
schizophrenia (59.1%) and bipolar disorder (46.4%; McClave et al., 2010).  
Depression and anxiety, both of which fall under the umbrella term of mood or affective 
disorders, are among the most prevalent MIs in the US. Depression affects 7.1% of the US adult 
population (NIMH, 2019b) and is marked by symptoms such as anhedonia (loss of 
interest/pleasure) and/or low affect (APA, 2013). Past two-week presence of anhedonia or low 
affect in combination with other symptoms such as loss of energy or excessive feelings of guilt 
warrants the diagnosis of major depression episode per the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-V; APA, 2013). Within the diagnoses of depression, the severity of 
impairment is mirrored in smoking rates. For example, 33.5% of those who experienced a major 
depressive episode with severe impairment reported current smoking while among individuals 
who experienced a major depressive episode without severe impairment, 30.5% reported current 






most prevalent MI in the US (Anxiety and Depression Association of America; ADAA, 2018). 
Smoking prevalence among individuals with anxiety disorders is higher than in the general 
population; a nationally representative survey (n=5,692) conducted between 2001 and 2003 
observed past 12-month daily smoking prevalence to be 33.9% for individuals with social 
anxiety disorder, 39.5% for panic disorder, 36.5% for generalized anxiety disorder, and 37.9% 
for posttraumatic stress disorder (Cougle et al., 2010), the latter of which was classified as an 
anxiety disorder in the DSM-IV (APA, 2000).  
These smoking rates highlight the severity of the public health threats associated with 
smoking within individuals who meet diagnostic criteria of an MI. However, some research 
suggests that lifetime reported depressed mood and anhedonia (separate from holding a clinical 
diagnosis) predict smoking cessation failure irrespective of lifetime depressive disorder diagnosis 
(Leventhal et al., 2014). Moreover, the link between smoking and depressive symptoms has been 
reported among individuals below the threshold for a clinical diagnosis, with greater symptom 
severity being linked to greater likelihood of being a current smoker as well as a decreased 
likelihood of successful quitting (Anda et al., 1990). Similar findings exist in regards to 
nonspecific psychological distress, which describes a dimension of somatic and psychological 
symptoms that are not linked to any single specific MI but are prevalent among those with 
affective disorders (Dohrenwend et al., 1980). In fact, most individuals with high psychological 
distress meet the diagnostic criteria for an MI (Lawrence el al., 2011). Among individuals who 
score moderately on a questionnaire measuring psychological distress, 33.9% are current 
smokers, and among those who score highly, 41.9% are current smokers (Lawrence et al., 2011). 
In addition to having a high smoking prevalence, populations with MI smoke with greater 






assessed the intensity of smoking among those groups focusing on prevalent MI, including 
depression and anxiety. A longitudinal study revealed that individuals suffering from major 
depression smoke significantly more cigarettes per day (CPD) relative to those not reporting 
major depression at age 17 to 18 (mean CPD 2.1 vs. 1.0) and age 20 to 21 (mean CPD 4.6 vs. 
2.6; Fergusson et al., 2003). For example,  while only 11.6% of a nationally representative 
sample reported past 12-month heavy smoking (i.e., at least 20 CPD), prevalence of heavy 
smoking was higher among those with anxiety, including individuals with social anxiety disorder 
(19.0%), panic disorder (22.4%), general anxiety disorder (25.5%), and posttraumatic stress 
disorder (24.0%; Cougle et al., 2010).  
Additionally, among a nationally representative sample of 23,635 adults, lifetime 
diagnosis of posttraumatic stress disorder was observed to be significantly and positively related 
to lifetime smoking status, nicotine dependence, and CPD (Greenberg et al., 2012). Smoking 
prevalence and intensity (as indexed by CPD) also are higher among individuals who report 
clinical depression and/or depressive symptoms (Leventhal et al., 2008). Because depressive 
symptoms are influenced by various psychopathologic factors, the relationship between 
depression and smoking is difficult to characterize by investigating the link between smoking-
related outcomes and depression associations (Leventhal et al., 2008). However, in regards to 
depression as well as other MI, several mechanisms have been identified that may help explain 
the patterns of smoking observed among individuals with MI.  
Mechanisms Underlying the Relationship Between Mental Health and Smoking 
The rewarding properties of nicotine, the dependence-producing chemical found in 






behaviors. However, other processes specific to smokers with MI also may explain the high 
smoking prevalence among this population compared to other groups.  
Pharmacology of nicotine. Nicotine can be absorbed via the bladder, the gastrointestinal 
tract, the skin, the buccal cavity, and the lungs (Schievelbein et al., 1973). When inhaling 
cigarette smoke, nicotine is transported into the lungs via inhaled smoke particles and then 
travels via the pulmonary veins into the arterial circulation (Benowitz, 2010). Via the 
bloodstream, nicotine then can cross the blood brain barrier, reaching the brain (Oldendorf, 
1974). Located across limbic and cortical brain regions are nicotinic acetylcholine receptors 
(nAChRs) which consist of ligand-gated ion channels (Benowitz, 2010). A set of proteins, α2-10 
and β2-4 are arranged around the pore of the nAChR channel; receptors comprised of two α4 
proteins and three β2 proteins play an important role in nicotine’s rewarding effects (Benowitz, 
2010). Nicotine, acting as an agonist, binds to and stimulates nAChRs, triggering the release of a 
range of neurotransmitters, including norepinephrine, serotonin, glutamate, beta endorphin, 
acetylcholine, and dopamine (Benowitz, 1999).  
A particular reward pathway plays a critical role in this process; nAChRs located in the 
ventral tegmental area (VTA) of the midbrain, facilitate release of dopamine into the nucleus 
accumbens (Dani & De Biasi, 2001). Meanwhile, nicotine triggers the glutamate release from 
glutamate neurons found in the frontal cortex, onto the neurons of the VTA, which then release 
dopamine (Mansvelder & McGehee, 2002). Additionally, nicotine desensitizes nAChRs located 
on γ-aminobutyric acid (GABA) neurons in the VTA (Mansvelder & McGehee, 2000, 2002). 
This desensitization results in a reduction of GABA release, which in turn leads to decreased 
VTA inhibition and subsequent increased dopamine release (Mansvelder & McGehee, 2000, 






produces pleasurable and rewarding sensations and is a characteristic shared by all drugs of 
abuse (Di Chiara & Imperato, 1988).  Dopamine increases in the shell of the nucleus accumbens 
have been shown to be nicotine dose-dependent with higher doses producing a greater 
concentration of dopamine (Nisell et al., 1997; Pontieri et al., 1996). Dopamine is also released 
into regions of the brain that are tasked with habit forming, learning, and emotional memory, 
including the dorsal striatum, the prefrontal cortex, and the amygdala (D'Souza & Markou, 2011; 
Laviolette, 2007; Schultz, 2007; Seamans & Yang, 2004). Dopamine produces a spectrum of 
effects that users perceive as desirable, and that reinforce the self-administration of nicotine, 
which in turn increases the likelihood of continued use and the subsequent development of 
tolerance and dependence.  
Development of tolerance and dependence. Positive and negative reinforcement 
processes contribute to the establishment and maintenance of nicotine dependence following the 
administration of nicotine-containing products such as cigarettes or ENDS (Benowitz, 2009; 
Eissenberg, 2004; Glautier, 2004). Nicotine functions as a positive reinforcer, thus increasing the 
likelihood of reoccurrence of smoking (Shadel et al., 2000).  Positive reinforcement occurs when 
the nicotine user experiences the pleasant and rewarding sensations resulting from nicotine 
administration. Dependent on dosage, nicotine also produces mild euphoria and heightened 
arousal (Watkins et al., 2000) or reduced arousal (Nesbitt, 1973) and increased relaxation 
(Silverstein, 1982). Moreover, nicotine is linked to improved concentration, learning, and 
attention (Levin et al., 2006). Positive reinforcement processes are at play especially when 
someone first begins to smoke (Glautier, 2004). However, as nicotine is administered repeatedly, 
neuroadaptation occurs, and the number of nicotinic binding sites on nAChRs is upregulated in 






2010; Wang & Sun, 2005). Regular smokers tend to keep nAChRs in a desensitized state during 
regular smoking (Benowitz, 2010; Brody et al., 2006).  
However, once nicotine is no longer administered, nAChRs become responsive again and 
nicotine abstinence-related symptoms begin to appear (Tidey et al., 2017; Wang & Sun, 2005). 
Smokers who undergo nicotine abstinence experience a range of aversive symptoms, including 
somatic symptoms such as gastrointestinal distress, headaches, and insomnia, and psychological 
symptoms including, but not limited to, anger, restlessness, concentration difficulties, and 
anxiety which can be suppressed by nicotine administration (Hughes et al., 1991). However, 
smoking-related stimuli even when not accompanied by nicotine, can also suppress some 
withdrawal symptoms; a double-blind, within-subjects study (n=32) revealed that nicotine-
containing and denicotinized cigarettes suppressed some withdrawal symptoms, including urges 
to smoke, to a similar degree, while other withdrawal symptoms, such as difficulty 
concentrating, could only be suppressed by nicotine-containing cigarettes (Buchhalter et al., 
2005).  
When nicotine is administered and the aversive symptoms (i.e., the aversive stimulus) are 
alleviated, negative reinforcement takes place and the likelihood of nicotine self-administration 
increases (Eissenberg, 2004). The transition from positive reinforcement-motivated nicotine 
administration to withdrawal avoidance is a pivotal time point in the substance use process, as 
previous use occurrences constituted non-dependent drug use, while the use in order to terminate 
aversive withdrawal effects present the beginning of dependent drug use (Eissenberg, 2004). As 
the use of a substance continues, counteradaptation occurs and neurobiological changes lead to 
an increase in a user’s hedonic setpoint; thus, substances, when administered in the same dosage 






that occurs during withdrawal (Koob & Le Moal, 1997). In addition to the dependence-
producing effects of nicotine, MI-related factors may contribute to the disproportionate 
prevalence and intensity of smoking among individuals with MI. A body of literature has aimed 
to isolate processes that may explain the smoking patterns among this population.  
 Bidirectional relationship between smoking and MI. Among the attempts to explain 
the nature of the relationship between MI and smoking, much attention has focused on the 
temporal precedence of one factor over the other. Some evidence has suggested that MI 
symptoms and smoking behavior can precede each other and thus form a reciprocal or 
bidirectional relationship (e.g., Leung et al., 2011; Ranjit et al., 2019). For example, a 
longitudinal epidemiologic study aimed to examine the role of smoking in among 1,007 young 
adults with first-onset major depression, as well as the role of major depression in their later 
smoking behavior (Breslau et al., 1998). Five-year follow-up data revealed that individuals who 
reported a lifetime diagnosis of major depression at baseline were three times more likely to 
report daily smoking at the five-year point; in turn, those who reported daily smoking at baseline 
were significantly more likely to report major depression at five-year follow-up (Breslau et al., 
1998). The notion of a reciprocal relationship between tobacco use and MI symptoms hold true 
for ENDS as well. For example, longitudinal data from 2,460 adolescents suggested that 
increased depressive symptoms at baseline served as a predictor of cigarette smoking, ENDS 
use, and dual use (Lechner et al., 2017). In turn, the same study observed that when compared to 
non-ENDS users, those who reported ongoing ENDS use across the 12-month duration of the 
study were significantly more likely to report an increase of depressive symptoms over time as 






While research reviewed here suggests that MI symptoms and tobacco use can influence 
each other, other results support the precedence of tobacco use over MI symptoms. For example, 
a longitudinal study using data from a nationally representative sample of 42,862 adults found 
that age at tobacco use initiation served as a predictor of lifetime major depressive disorder later 
in life (Hanna & Grant, 1999). Relative to nonsmokers, smokers who reported initiating smoking 
prior to age 13 were almost twice as likely to report lifetime major depressive disorder and 
reported significantly more major depressive episodes than late-onset smokers and nonsmokers, 
suggesting that tobacco may serve as a precipitant of depressive disorders (Hanna & Grant, 
1999). Similarly, analyses of data derived from two semi-structured interviews of 1,709 
adolescents spaced 12 months apart observed that individuals who reported current smoking at 
baseline were almost twice as likely to report a major depressive episode during the subsequent 
12 months (Brown et al., 1996). Other data suggest a similar pattern related to anxiety symptom 
development. Analyses of two longitudinal nationally representative epidemiologic studies using 
samples of 1,007 and 4,411 individuals revealed that daily cigarette smoking was linked to an 
almost four-fold risk of reporting a panic attack later on, while there was no evidence that the 
presence of panic attacks predicted daily smoking at a later time point (Breslau & Klein, 1999). 
However, while this particular study did not find symptoms of MI to predict later tobacco 
smoking, other findings indicate the opposite. In fact, some research suggests that smoking 
taking place post-symptom onset may serve a specific purpose for smokers with MI, namely the 
alleviation of the MI symptom severity.  
Self-medication hypothesis. In contrast to the use of nicotine to alleviate negative and/or 
adverse symptoms associated with nicotine abstinence, the self-medication hypothesis describes 






associated with a behavioral illness that preceded exposure to the substance (Goldstein, 1987; 
Khantzian, 1997). Much work has investigated the effects of smoking on the reduction of 
symptoms associated with MI, suggesting that nicotine and/or smoking may be effective in 
producing symptom relief. For example, an in-lab experiment using a within-subjects design 
recruited six minimally nicotine-deprived smokers to complete three counterbalanced sessions 
differing in cigarette-delivered nicotine administration, including smoking of an own brand 
cigarette, not smoking, and smoking a zero-nicotine cigarette (Pomerleau et al., 1984). Anxiety 
was induced by prompting the participants to solve an unsolvable anagram in a short period of 
time, thus producing task failure among participants while being observed by the researcher 
(Pomerleau et al., 1984). Thirty minutes prior to all sessions, participants smoked a cigarette to 
ensure minimal nicotine deprivation. Anxiety symptoms were assessed immediately before and 
after the nicotine administration manipulation. The own brand condition resulted in significantly 
greater decreases in anxiety relative to the zero-nicotine cigarette condition (Pomerleau et al., 
1984). However, the potentially symptom-alleviating effects of nicotine are not limited to 
anxiety. For example, the role of nicotine in the symptom regulation of individuals with 
attention-deficit/hyperactivity disorder (ADHD) has received attention. A cross-sectional 
analysis of a small subsample of 23 community youth with ADHD observed that non-medicated 
individuals were significantly more likely to report lifetime or current cigarette smoking (Whalen 
et al., 2003). Authors here hypothesized that the higher rate of smoking among non-medicated 
individuals may have been due to the individuals’ attempts to self-medicate with nicotine to 
improve negative affect, attention, and impulsivity (Whalen et al., 2003).  
The construct of smoking expectancies, i.e., the anticipation of smoking-related 






considering the self-medication hypothesis. Smoking expectancies have been suggested to 
influence intensity of smoking (Brandon & Baker, 1991). This finding may imply that smoking 
may not indeed produce true symptom alleviation but that increased smoking upon stress occurs 
solely due to smokers’ expectations of subsequent mood improvement. However, while smoking 
expectancies undoubtedly play a role in the maintenance of smoking behavior, several studies 
have been conducted that investigate the effects of nicotine specifically on nonsmokers’ 
symptoms of MI (i.e., to understand nicotine’s effects among on individuals who do not have 
established smoking expectancies).  
For example, in randomized double blind study aimed to investigate the effects of 
nicotine administration on ADHD symptoms and continuous performance test outcomes, 40 
nonsmoking adults with ADHD were assigned to four conditions including control, 
methylphenidate (20 mg), nicotine (delivered via patch), and nicotine and methylphenidate 
(Levin et al., 2001). Nicotine and/or methylphenidate was administered for four weeks, with the 
nicotine concentration starting with 5 mg daily during week 1, 10 mg daily during week 2 and 3, 
and 5 mg during week 4 (Levin et al., 2001). On the first day of drug administration, transdermal 
nicotine was associated with significant decreases in ADHD symptom severity; however, the 
effects of nicotine on ADHD symptoms was no longer detectable during the chronic 
administration phase (Levin et al., 2001). Another longitudinal study randomly assigned 24 
nonsmokers who met criteria for major depressive episodes and reported insomnia to receive 
either nicotine patches (17.5 mg) or fluoxetine (20 mg; Haro & Drucker-Colin, 2004a). Dosages 
and administration frequency were maintained until 6 months post-baseline, then administered 
less frequently, and eventually replaced with a placebo (Haro & Drucker-Colin, 2004a). Rapid 






well as depression scores improved significantly across both groups. For the nicotine group, 
analyses of polysomnographic recordings suggested improvements in slow wave sleep, sleep 
efficiency index scores, and overall sleep duration, with small decreases in time spent in REM 
sleep during nicotine withdrawal (Haro & Drucker-Colin, 2004a). The same authors conducted a 
single-blind clinical study during which nicotine patches (17.5 mg) were administered to 14 
nonsmokers with major depression for six months and then tapered off until the end of the 24-
month long study until participants received a placebo patch (Haro & Drucker-Colin, 2004b). 
Improvements in depression scores were reported; at the end of the study, participants reported a 
63.5% decrease in depression scores, with a >50% decrease observed in 78.6% of participants. 
Moreover, REM latency values approached levels seen in non-depressed populations (Haro & 
Drucker-Colin, 2004b). Taken together, these three examples support the idea that nicotine 
administration alone (not nicotine-related expectancies) can improve measures of mental 
health/cognition among those with MI. However, additional factors, including social and 
environmental factors exist that may contribute to the prevalence of smoking among individuals 
with MI.  
Social and environmental factors. Social and environmental factors contribute to 
shaping the smoking patterns among individuals with MI. One of the factors that has been 
implicated in contributing to the high smoking rates among individuals with MI is proximity and 
density to tobacco retailers; a study geocoded the addresses of 1061 smokers and assessed the 
proximity to the nearest tobacco retailer as well as the number of retailers available nearby 
(Young-Wolff et al., 2014). Findings revealed that smokers with severe MI clustered around 
neighborhoods in which the tobacco retailer density was twice as high relative to their 






diagnosis, greater tobacco retailer density was observed to be significantly related to impaired 
psychosocial functioning as indexed by reported self-injurious behavior, interpersonal 
difficulties, and psychosis (Young-Wolff et al., 2014). Additionally, social status influences 
smoking among individuals with MI. A study with a sample of smokers and nonsmokers with 
severe MI (n=240) observed that objective social status as indexed by several factors including 
annual income and education was significantly related to smoking status with those lower in 
social status having a greater likelihood of being smokers (Langlois et al., 2020). Additionally, 
social status was also significantly related to nicotine dependence among individuals with severe 
MI, with lower social status being related to greater nicotine dependence (Langlois et al., 2020). 
These studies highlight the influence of social and environmental factors on smoking patterns 
among individuals with MI, suggesting that neighborhood-related factors such as easy access to 
tobacco products and lower social status may exacerbate smoking among individuals with MI.  
 Summary. The literature reviewed here describes some mechanisms commonly 
implicated in the development of nicotine dependence among the general smoking population as 
well as specific processes hypothesized among individuals with MI. In addition to these factors 
that may contribute to the maintenance of smoking, barriers may exist that make quitting and 
harm reduction approaches in this vulnerable subgroup of smokers more challenging.  
Smoking Cessation/Harm Reduction Challenges among Smokers with Mental Illness 
Due to the highly addictive nature of nicotine delivered via cigarettes, smokers encounter 
significant difficulties when attempting to stop smoking (Babb et al., 2017) or reduce cigarettes 






experience additional barriers to successful smoking cessation, which are reflected in the low 
quitting rates among this population. 
For example, a population-based cross-sectional survey using 4,411 individuals observed 
that relative to smokers without MI who reported quit rates of 42.5%, both smokers with past-
month MI (30.5%) and smokers with lifetime MI (37.1%) reported significantly lower quit rates 
(Lasser et al., 2000). Additionally, a large-scale population-based survey using data from 
142,000 adults observed that lifetime daily smokers who reported past-year MI were more likely 
to be current smokers (61.6%) relative to lifetime daily smokers without past-year MI (47.2%; 
Lipari & Van Horn, 2017). For example, smoking cessation after a 9-year follow up was 17.7% 
for smokers classified as non-depressed and 9.9% for smokers classified as depressed via self-
report measure using a cutoff score at baseline (Anda et al., 1990).  
Additionally, a cross-sectional study using population-based data from 3,213 individuals 
observed that ever smokers who suffered from major depressive disorder were significantly less 
likely to have quit smoking relative to their counterparts without major depressive disorder 
(Glassman et al., 1990). Similarly, a smoking cessation treatment study of 1,469 daily smokers 
identified anhedonia, a symptom of depression, to be linked to significantly lower 7-day quit 
rates (Leventhal et al., 2014). A large cross-sectional population-based survey using data from 
248,800 individuals observed that reports of lifetime diagnosis of depression, anxiety, and dual 
diagnoses of depression and anxiety were most frequent among smokers who reported failed quit 
attempts, and lowest among those reporting successful smoking cessation (McClave et al., 2009). 
Smokers who reported failed quit attempts also reported greater severity of depressive 
symptoms, while those who quit successfully reported the lowest levels of depression (McClave 






Other psychological factors present barriers as well. For example, a trial involving 732 
smokers with and without MI indicated that stress was cited significantly more frequently as a 
reason for cessation relapse across smokers with anxiety and depression relative to smokers 
without MI (Tulloch et al., 2016). Negative affect also was reported more frequently as a reason 
for cessation relapse by participants with anxiety, depression, and bipolar disorder. The same 
study also investigated cessation-specific concerns; relative to smokers without MI, smokers 
with anxiety disorders were significantly more likely to report fear of failure, mood, and stress as 
cessation-related concerns (Tulloch et al., 2016). Moreover, relative to smokers without MI, both 
smokers with psychotic disorders and smokers with anxiety disorders were significantly more 
likely to report boredom as a cessation-related concern (Tulloch et al., 2016).  
Nicotine dependence-related factors present barriers as well. While no significant 
between-group differences were observed across MI categories for reported concerns about 
cravings, the majority (55.6%) of individuals with lifetime psychotic disorders and about one 
third of individuals with anxiety (31.9%) and depression (27.2%) reported cravings as a 
cessation-related concern (Tulloch et al., 2016). Also, a four-week smoking cessation study 
(n=81) comparing contingency management smoking treatment to standard smoking treatment 
revealed that smokers with high levels of depressive symptoms at baseline reported an increase 
of withdrawal symptoms and smoking urges during week 1, while smokers with low levels of 
depressive symptoms reported a decrease in withdrawal symptoms and smoking urges during the 
first week (Reid & Ledgerwood, 2016). Additionally, relative to smokers who reported low 
levels of depressive symptoms at baseline, those who reported high levels of depressive 
symptoms at baseline reported higher levels of nicotine withdrawal throughout the entire study 






cessation treatment study (n=1,469) found smokers with depressed mood as well as those who 
specifically reported anhedonia to be at a significantly greater risk of relapse relative to their 
counterparts without depressed mood (Leventhal et al., 2014). Thus, depressive symptoms 
present a risk factor for cessation complications (e.g., increased nicotine withdrawal at the start 
of cessation) as well as relapse and should be considered when evaluating the effectiveness of 
smoking cessation or harm reduction approaches, as they may influence rates of success 
particularly among smokers with MI. 
Social and environmental factors likely contribute to the reduced likelihood of quitting 
smoking as well. For example, greater tobacco retailer density in one’s neighborhood has been 
found to be significantly related with lower self-efficacy for smoking cessation (Young-Wolff et 
al., 2014). Moreover, a systematic literature review of qualitative and quantitative studies on 
barriers among vulnerable populations found that such populations, including smokers with MI, 
live in environments in which smoking is common and acceptable and that being around other 
smokers was perceived to be a barrier (Twyman et al., 2014). 
An additional factor leading to a discrepancy in cessation rates among smokers with and 
without MI exists at provider-level in the healthcare system. A survey of all known private and 
public substance use treatment facilities in the US (n=5,737) identified a lack of access to 
cessation resources; only 42% of all surveyed facilities provided smoking cessation services 
(SAMHSA, 2013). Other provider-level barriers include the gross underestimation of healthcare 
providers’ perceptions of smokers’ willingness to quit. For example, when 231 smokers with 
severe MI who were patients at community mental health centers were surveyed about their 
cessation interest and treatment, interest in taking cessation medication was reported by 44.0%, 






while 25.0% reported interest in undergoing cessation counseling, only 5.4% reported current 
cessation counseling (Chen et al., 2017). Such findings may be linked to a underestimation of 
interest in smoking cessation among smokers with MI; results from the same survey indicated 
that while 82.0% of smokers with severe MI reported wanting to quit or reduce their cigarette 
intake, over 90.0% of the psychiatrists surveyed reported that the perceived lack of interest in 
smoking cessation among their patients with severe MI presented a barrier to implementing 
cessation efforts (Chen et al., 2017).  
Social and environmental factors as well as MI symptom-related factors, nicotine 
dependence-related factors, and provider-level factors constitute some of the barriers that prevent 
smokers with MI from successful cessation, despite several smoking cessation and harm 
reductions being available for smokers, including smokers with MI.  
Smoking Cessation/Harm Reduction Treatment Approaches for Those with Mental Illness 
Smoking treatment approaches for individuals with MI typically mirror those 
implemented among the general smoking population and it remains unclear if smokers with MI 
derive greater benefits from cessation treatments specifically tailored to MI symptoms relative to 
traditional treatment (Baker et al., 2004). The US Food and Drug Administration (FDA) has 
approved seven first-line medications for the treatment of tobacco use (Fiore et al., 2008). While 
some of the first-line medications contain nicotine, some do not, and all have been deemed to be 
generally safe (Little & Ebbert, 2016) as well as effective in aiding adult smoking cessation 
(Fiore et al., 2008). Additionally, counseling delivered across various settings is considered 
effective. It is critical to provide aid to smokers during cessation attempts, as unaided quit 
attempts are only successful in 4% to 7% of smokers (Fiore et al., 2008). Ideally, treatment 






altogether. However, in cases where complete abstinence may not be possible, the alternate goal 
of harm reduction may be pursued (Hughes, 1995; Kozlowski, 1989), meaning that if a behavior 
such as smoking is continued, harm potential should be reduced to a minimum if possible, which 
can include nicotine delivery through alternative, less harmful methods (Britton & Edwards, 
2008). 
 Nicotine replacement therapy (NRT) products are administered in order to replace the 
nicotine in the body typically derived from smoking and subsequently alleviate nicotine 
withdrawal symptoms and decrease the desire to smoke (Silagy et al., 2004). For this purpose, 
the FDA has approved multiple NRT products including nicotine gum, lozenge, nasal spray, 
inhaler, and the transdermal patch (Fiore et al., 2008). NRT products differ in their dose and 
speed of nicotine delivery over time. For example, relative to the 5-10 minutes that cigarette-
derived nicotine takes to be absorbed, nicotine that is delivered via a nicotine gum and absorbed 
through the buccal mucosa takes about 30 minutes (Russell et al., 1980). Nicotine delivery time 
is critical as smoking cigarettes allows the user to titrate their plasma nicotine concentrations 
during the day particularly in response to nicotine cravings that may arise (Sweeney et al., 2001).  
To prevent relapse, combination NRT therapy may be offered to smokers in order to 
address components of nicotine dependence. Benefits of this approach have been noted in a 
meta-analysis including 63 randomized controlled trials (RCTs; n=41,509) with greater cessation 
success rates at 6-month follow-up when a slow acting NRT (i.e., patch) was combined with a 
fast acting NRT (e.g., gum; Lindson et al., 2019). In addition to how quickly nicotine is 
delivered, the dose of nicotine dose delivered plays a role in cessation success, with higher 
dosages of nicotine being linked to greater likelihood of long-term cessation; e.g., cessation rates 






Two non-nicotine medications are currently FDA-approved and marketed for smoking 
cessation. Bupropion mimics the stimulant effects typically associated with nicotine, thus 
promoting suppression of nicotine abstinence-related withdrawal symptoms and subsequently 
preventing smoking relapse by blocking the reuptake of norepinephrine and dopamine as well 
via the blocking of nAChRs (Fiore et al., 2008; Warner & Shoaib, 2005). Similarly, varenicline, 
a partial nAChR agonist, inhibits nicotine from binding to its respective receptors, thus slowing 
the release of dopamine while decreasing negative symptoms associated with nicotine abstinence 
(Kaur et al., 2009).  
 Behavioral treatment has been established as an integral factor in smoking cessation with 
several approaches deemed effective, including counseling by a professional in a face-to-face 
setting, group counseling, phone counseling, and self-help programs, the latter of which can 
consist of printed or electronic materials (Crain & Bhat, 2010). Cognitive behavioral therapy can 
teach smokers to cope with negative symptoms associated with nicotine abstinence as well as 
associated mood effects and smoking urges. This method focuses on motivational and behavioral 
factors associated with smoking (Crain & Bhat, 2010). Intensive smoking cessation support 
includes residential programs, where severely nicotine dependent individuals suffering from 
comorbid conditions such as medical conditions and/or substance use disorders can receive 
behavioral counseling, education, pharmacotherapy, and group therapy (Crain & Bhat, 2010). 
Newer behavioral treatment approaches make use of mobile technology; relative to a control 
condition, moderate effectiveness was found for text message cessation programs, regardless of 
whether such programs included an in-person or online counseling component or consisted 






 Effectiveness of available treatments in smokers with MI. Smokers with MI 
experience a set of psychological stressors that may present barriers to successful smoking 
cessation. However, some research describes effective cessation methods for smokers with MI. 
For example, a review of results from eight RCTs that included n=10 to n=298 of smokers with 
schizophrenia, “psychotic disorder”, or schizoaffective disorder, assessed point prevalence 
abstinence and/or smoking reduction at different time points for different treatment methods, 
using meta-analysis to when treatment and comparisons were deemed similar (Banham & 
Gilbody, 2010). Findings revealed that relative to traditional care, NRT in combination with 
individual therapy produced significantly greater rates of smoking abstinence among smokers 
with severe MI at four-month follow-up (risk ratio; RR=2.74) relative to smokers with severe MI 
randomized to receive standard care consisting of access to community mental health teams and 
general practitioners (see Baker et al., 2006). However, significant differences were no longer 
observed at seven-month follow up (Banham & Gilbody, 2010). Bupropion plus group therapy 
was found to be more effective relative to placebo combined with group therapy at trial endpoint 
(RR=4.18; Banham & Gilbody, 2010). Moreover, bupropion in combination with group therapy 
and NRT produced greater abstinence rates relative to group therapy combined with NRT 
(RR=2.34); additionally, bupropion was more effective than placebo in producing smoking 
abstinence (RR=2.77). Smoking reduction (≥ 50% reduction of CPD from baseline) could not be 
investigated using a meta-analysis given the differences in outcomes and time points across 
different studies. The authors of the literature review reported that no significant differences in 
smoking reduction rates was found in the RCTs included between NRT and placebo, between 
NRT plus group therapy, or group therapy alone (Banham & Gilbody, 2010). However, relative 






(RR=2.62), and group therapy in combination with bupropion was more found to be more 
effective for smoking reduction than group therapy alone at the three-month time point (Banham 
& Gilbody, 2010).  
 Smokers with current depression were more likely to be abstinent at 6-month follow-up 
or longer relative to control when a psychosocial mood management factor (mostly a cognitive 
behavioral therapy component) was added to cessation treatment (RR=1.47), as suggested by a 
meta-analysis of 11 RCTs (n=1,844; van der Meer et al., 2013). Similarly, a meta-analysis of the 
results of 13 RCTs (n=1,496) suggested that adding psychosocial mood management to the 
standard smoking intervention was helpful for smokers with past depression (RR=1.41; van der 
Meer et al., 2013). In regards to the effectiveness of bupropion for smokers with current 
depression, a meta-analysis of eight RCTs (n=517) suggested that bupropion is effective relative 
to placebo (RR=1.32), as is bupropion in combination with NRT relative to NRT alone 
(RR=1.93; van der Meer et al., 2013). Similarly, bupropion was effective among smokers with 
past depression relative to placebo (RR=1.57), as well as when used in conjunction with NRT 
relative to placebo and NRT (RR=5.46; van der Meer et al., 2013). Lastly, a prospective cohort 
study aiming to estimate the prevalence of varenicline and NRT prescriptions among more than 
13 million primary care patients in the United Kingdom found that smokers with MI who were 
prescribed varenicline had a 19.0% greater likelihood to have quit smoking at two-year-follow 
up relative to smokers with MI who were prescribed NRT (Taylor et al., 2020). However, the 
study also found that smokers with MI were 31.0% less likely to receive a varenicline 
prescription relative to smokers without MI (Taylor et al., 2020). The FDA has recently removed 
the black box warning advising individuals of severe side effects, including worsening mood 






frequently in the future. The aforementioned study suggests that while some treatment methods 
may indeed be effective for smokers with MI, barriers indirectly related to some smokers’ MI 
symptoms (e.g., providers’ hesitation to prescribe treatment medications based on the patient’s 
MI status) may in turn render such treatments ineffective due solely to non-administration. 
Overall, while NRT and other FDA-approved smoking cessation medications and behavioral 
counseling methods such as cognitive behavioral therapy have been found to be safe and 
effective among individuals with MI, short and long-term smoking rates among this population 
remain high, suggesting a need for alternative treatment options or improved treatment for this 
group of smokers.  
ENDS Use, Nicotine Delivery, and Use Among Individuals with MI 
The body of evidence regarding the effectiveness of nicotine and non-nicotine smoking 
cessation treatments suggests there is room for improvement among these approaches, 
particularly for individuals with MI. Although no ENDS are legally marketed for therapeutic use 
by US-based manufacturers, public and scientific interest in the ability of ENDS to reduce harm 
among conventional tobacco users remains high.  
What are ENDS? This tobacco product class represents a diverse group of electronic 
devices that consist of a reservoir designed to hold a liquid solution, a battery or other power 
source, and a heating element (Hiler et al., 2017). The liquid solution typically contains 
vegetable glycerin and/or propylene glycol, which act as solvents, and flavorings (e.g., tobacco, 
menthol; Breland, 2017) and may, but does not always, contain nicotine. Some ENDS are puff-
activated, while others are activated through the push of a button located on the device. Upon 






users can inhale (Breland, 2017). Nicotine found in ENDS liquid solution varies in its form 
(pronated vs. non-pronated) which has implications for nicotine yield and delivery (El-Hellani et 
al., 2018). The nicotine concentration in most liquid solutions ranges from 0 mg/ml to 36 mg/ml 
(Breland, 2017) but nicotine concentrations in newer products such as JUUL can range upwards 
to 69 mg/ml (Talih et al., 2019).  
Some ENDS products are about the size of a traditional cigarette and are called “first-
generation devices” or “cigalikes” (Malek et al., 2018). Such first-generation ENDS are not 
designed for the user to refill the liquid once it is has been used (i.e., closed ENDS system) and 
do not give the user the ability to substitute the initial device-linked heating element or battery 
with other models. However, other ENDS products (often termed “second-generation devices”) 
exceed the size of a traditional cigarette by far and have a tank to store the liquid and a battery 
detached from tank or cartridge (Breland et al., 2017). Second-generation devices typically are 
equipped with rechargeable batteries, refillable tanks, as well as features that can be adjusted by 
the user, including voltage (Harvanko et al., 2017). In comparison, third-generation ENDS 
devices are equipped with even more adjustable features relative to second-generation ENDS 
devices (Harvanko et al., 2017). Across the different device generations, differences in nicotine 
delivery and potentially harmful exposures have been found due to a spectrum of ENDS device 
and liquid characteristics (Breland, 2017; Talih et al., 2015). So-called pod mods such as JUUL 
exceed the nicotine delivery of non-cartridge-based ENDS models and resemble traditional 
cigarettes in their nicotine delivery profile (Hajek et al., 2020); however, nicotine delivery profile 
of JUUL relative to traditional cigarettes may be dependent on user experience (Prochaska et al., 






associated with nicotine abstinence may play a critical role in the promotion of ENDS for 
smoking cessation and/or reduction.   
Nicotine Delivery from ENDS 
As previously mentioned, negative reinforcement is one of the mechanisms through 
which ongoing nicotine self-administration is maintained. Among smokers, if nicotine delivery is 
ineffective from an alternative nicotine delivery product (e.g., ENDS), symptom suppression is 
likely to be incomplete, thus potentially increasing the likelihood an individual may relapse to 
their referred source of nicotine delivery. Among ENDS with nicotine-containing liquid solution, 
the effectiveness of nicotine delivery differs as a function of various factors including the device 
itself, liquid (i.e., nicotine concentration), and user history with ENDS.  
Early studies of first-generation ENDS suggested that these products were ineffective in 
delivering nicotine to users. For example, a within-subjects experiment of 32 nicotine-deprived 
cigarette smokers involved conditions differing by product: own-brand cigarette, unlit cigarette 
(placebo), and two first-generation ENDS (one with liquid containing a 16 mg/ml and the other 
with liquid containing 18 mg/ml of nicotine). Unlike own-brand cigarette smoking, neither 
ENDS condition significantly increased plasma nicotine concentrations or heart rate after two 
10-puff bouts of use (Vansickel et al., 2010). Use of own-brand cigarettes and both ENDS led to 
significant decreases in participants’ symptoms of nicotine-related abstinence symptoms while 
the placebo did not (Vansickel et al., 2010). A similarly designed study indicated that a second-
generation ENDS was more effective than a first-generation ENDS in delivering nicotine when 
loaded with the same nicotine concentration liquid (18 mg/ml; Farsalinos et al., 2014). Using a 






standardized ENDS puffs followed by one hour of ad lib ENDS use. Across all measurement 
points, the second-generation ENDS produced greater plasma nicotine concentrations relative to 
first-generation ECIG. These condition-related differences in plasma concentrations were 
mirrored in self-reported cravings, which were significantly lower among participants in the 
second-generation ENDS condition relative to the first-generation ENDS condition (Farsalinos et 
al., 2014). Yet another in-lab experiment sought to compare the nicotine delivery of second-
generation devices to those of third-generation devices. Exclusive ENDS users of second-
generation devices (n=9) and third-generation devices (n=11) were recruited to complete a 
standardized 10-puff bout and a subsequent ad lib period using their own brand liquid and ENDS 
(Wagener et al., 2017). Importantly, mean (SD) nicotine concentrations in the liquid solutions of 
second-generation ENDS users were found to be 22.3 (7.5) mg/ml, which substantially exceeded 
the 4.1 (2.9) mg/ml found among third-generation ENDS users (Wagener et al., 2017). Yet, users 
of the third-generation devices achieved greater plasma nicotine concentrations compared to 
second-generation users at several time points throughout the session (Wagener et al., 2017). Of 
note, third-generation ENDS’ heating elements had lower resistance relative the second-
generation devices and consequently higher power than the second-generation devices used in 
this study (Wagener et al., 2017). Taken together, these data highlight the influence of ENDS 
device features on nicotine delivery capability. 
Another experimental lab-based study highlights the influence of liquid nicotine 
concentration and ENDS use history on nicotine delivery and nicotine abstinence-associated 
effects when ENDS device features are held constant (Hiler et al., 2017). Here 33 ENDS-
experienced users and 31 ENDS-naive smokers completed four sessions that differed by the 






device was an “eGo” style with non-adjustable voltage settings similar to those described as 
second-generation ENDS (Caponnetto et al., 2017). The ENDS consisted of a 3.3 volt battery 
and a 1.5 Ohm cartomizer. Participants completed two standardized 10-puff bouts with a 30-
second interpuff interval separated by 60 minutes. Plasma nicotine concentrations differed by 
ENDS use history, condition, and time with ENDS-experienced users achieving the dose-related 
increases in plasma nicotine as well as significantly greater plasma nicotine concentrations 
during nicotine-containing conditions compared to ENDS-naive users (see Table 1).  Effects for 
nicotine abstinence-related symptoms indicated that greater suppression was observed among 
ENDS-experienced participants with the higher nicotine concentration liquid conditions (which 
resulted in the greatest nicotine delivery). One important contributor to these effects were 
differences in puff topography (i.e., puffing behavior) between user groups with experienced 
users taking larger (in volume) and longer puffs (even though puff number was held constant). A 
systematic review of studies measuring ENDS puff topography indicated that average puff 
duration was significantly longer compared to cigarette smoking and appeared to require 
“stronger suction” (Evans & Hoffman, 2014). This finding suggests that cigarette smokers may 
need to adapt their puffing behavior to achieve effective nicotine delivery and associated nicotine 
abstinence symptom suppression when initiating ENDS use.  
Table 1. Nicotine boost from nicotine-containing-ENDS conditions after 10 puffs (30 sec IPI) by 
user experience (data are in ng/ml) 
 8 mg/ml* 18 mg/ml* 36 mg/ml* 
ENDS-experienced 8.2 (7.8)  13.0 (6.2)  17.9 (17.2)  
ENDS-naive 3.6 (3.9)  6.2 (10.2)  6.8 (7.1)  
 
Total sample 6.0 (6.6)  10.0 (12.2)  13.0 (14.3)  
Note: Table adapted from Hiler et al., 2017; * indicates significant difference by ENDS use 







 Variability in ENDS nicotine delivery likely offers one explanation for the varying 
effectiveness observed among the few published RCTs of ENDS for smoking cessation and/or 
harm reduction. Findings from the most recent Cochrane review included two RCTs (combined 
n=662), suggesting that smokers randomized to use nicotine-containing ENDS were 2.29 times 
as likely to achieve smoking cessation relative to smokers randomized to use non-nicotine-
containing ENDS (Hartmann-Boyce et al., 2021). A 2018 systematic review undertaken by the 
National Academies of Sciences, Engineering, and Medicine concluded that there was “limited 
evidence” that ENDS are effective for smoking cessation, but their use as a complete substitute 
for cigarettes had “conclusive evidence” of reductions in toxicant exposure reduction and having 
“substantial evidence” for reduced short-term adverse health outcomes (National Academies of 
Sciences, Engineering, and Medicine, 2018). Closer examination of the current evidence 
regarding ENDS for smoking cessation and harm reduction efforts reflects this ambiguity.  
ENDS for Smoking Cessation and Reduction  
Among the larger (>200) and longer-term (>3 months) RCTs that have examined the 
effectiveness of ENDS for smoking behavior change, there has been mixed evidence on the role 
of nicotine dose/delivery. An RCT performed in New Zealand investigated the effects of a first 
generation ENDS (10-16 mg/ml nicotine) relative to a placebo ENDS (no nicotine) to nicotine 
patches (21 mg/24 h nicotine patches) on cessation in smokers (n=657) interested in quitting 
(Bullen et al., 2013). Overall quitting rates (6 months continuous abstinence) did not 
significantly differ from one another and were low across the three groups, including for the 
nicotine ENDS condition (7.3%), the non-nicotine-containing condition (4.1%) and the nicotine 
patch condition (5.8%); authors highlight a lack of statistical power as a possible reason for the 






RCT performed in Italy assigned smokers (n=300) not wanting to quit to one of three ENDS 
conditions with different nicotine concentrations (7.2 mg/ml nicotine, 5.4 mg/ml, and 0 mg/ml; 
Caponnetto et al., 2013). All three groups had significant decreases in CPD at week 52 with no 
significant between-group differences observed; across all groups, 8.7% were tobacco abstinent 
at week 52 (Caponnetto et al., 2013). On an intention-to-treat basis and excluding those who quit 
smoking, 14.5% in the nicotine-containing groups and 12.0% in the non-nicotine-containing 
groups reported at least a 50% reduction in CPD at 52 weeks (Caponnetto et al., 2013). In 
another large-scale RCT performed in the United Kingdom, participants (n=886) were assigned 
randomly to receive either a three-month supply of NRT product(s) of their choice or a second-
generation ENDS (liquid nicotine concentration of 18 mg/ml) coupled with behavioral support 
for both groups (Hajek et al., 2019). One-year sustained abstinence (self-report of smoking <= 5 
cigarettes from 2 weeks after the target quit date; CO <8 parts per million [ppm]) was 
significantly more prevalent in the ENDS condition (18.0%) than in the NRT condition (9.9%; 
Hajek et al., 2019). Among participants who were not abstinent, significant condition-related 
differences were found in smoking reduction, with 12.8% of ENDS condition participants 
reporting a 50% reduction relative to 7.4% of NRT participants (Hajek et al., 2019).  
Another pragmatic, randomized trial enrolled ENDS-naive smokers and assigned them to 
one of three 14-week-long conditions, including nicotine patch only (n=125), nicotine patch plus 
nicotine-containing ENDS (n=500), and nicotine patch plus an ENDS with no nicotine (n=499). 
Participants were advised to use the nicotine patch daily and to use the ENDS as needed. 
Nicotine patches in combination with a nicotine-containing ENDS lead to a modest improvement 






significantly higher than the quit rate from using patches plus a nicotine free ENDS (4%) or 
nicotine patches alone (2%; Walker et al., 2020).   
An RCT conducted in Canada randomized adult smokers motivated to quit to conditions 
using either no ENDS at all, ENDS with 0 mg/ml of nicotine, or ENDS with 15 mg/ml of 
nicotine (Eisenberg et al., 2020). Individual smoking cessation counseling was provided to all 
groups. At 90-day follow-up, significantly more participants among those randomized to the 
nicotine-containing ENDS condition plus counseling reported greater 7-day point prevalence 
abstinence relative to those who had only received counseling (21.9% vs. 9.1%). However, no 
significant differences were found between those randomized to the 0 mg/ml of nicotine ENDS 
plus counseling and those assigned to counseling alone (17.3% vs 9.1%; Eisenberg et al., 2020). 
No significant differences in reported 7-day point prevalence abstinence between participants 
using ENDS with and without nicotine were found at 12-week and 24-week follow-up 
(Eisenberg et al., 2020).  
These RCTs and others (Maserio et al., 2019; Halpern et al., 2018) underscore the 
potential utility of ENDS for smoking cessation and reduction efforts as well as relatively low 
levels of efficacy for FDA-approved treatments among adult smokers. Considering individuals 
with MI are at increased risk for smoking and development of nicotine dependence and have 
barriers to treatment, more information is needed regarding how ENDS could potentially be 
useful ENDS in this population.  
Use behaviors and perceptions of ENDS among individuals with mental illness. 
Similar to higher rates of smoking among individuals with MI, ENDS also appear to be used to a 






survey of 10,041 adults indicated that the likelihood of having tried ENDS was more than twice 
as high (14.8%) for individuals with lifetime MI relative to their counterparts without lifetime 
MI (6.6%; Cummins et al., 2014). Significant differences in ever ENDS use among smokers 
specifically were also noted with 40.3% of current smokers with MI reporting ever use of ENDS 
relative to 28.7% of their counterparts without MI (Cummins et al., 2014). More recent reports of 
ENDS use among populations with MI describe similar patterns. A 2015 nationally 
representative cross-sectional survey among 6,051 adults indicated that ENDS ever use was 
significantly higher among individuals with MI (24.4%) relative to those without MI (15.5%; 
Spears et al., 2017). Moreover, there was a positive relationship between the number of lifetime 
MI diagnoses reported and ever ENDS use, with 15.5% of individuals reporting no MI, 19.8% of 
individuals reporting two MI, and 42.3% of individuals reporting three or more MI also reporting 
ENDS ever use (Spears et al., 2019). Similarly, findings from a large-scale, cross-sectional study 
performed in 2016/2017 (n=892,394) suggested that current and former ENDS users were more 
likely to report lifetime depressive disorder and poor mental health relative to never ENDS users 
(Obisesan et al., 2019).  
While the literature suggests that lifetime diagnoses of MI may increase the likelihood of 
ENDS use, other research suggests that even psychological distress may be linked to increased 
likelihood of ENDS use. A nationally representative survey of 36,697 adults found that 
individuals who scored higher on a measure of psychological distress were 3.7 times more likely 
to have ever used ENDS exclusively (Park et al., 2017). Moreover, those higher in psychological 
distress were 3.2 times more likely to have ever used ENDS and be a former smoker, 4.6 times 






exclusive ENDS users, with authors noting an increase in odds ratios mirroring increases in 
psychological distress (Park et al., 2017).  
These ENDS use patterns may also be influenced by ENDS perceptions among smokers 
with MI. Specifically, past research has suggested that smokers with MI perceive ENDS as 
socially acceptable, less harmful to others, and an effective tool for smoking cessation (Baltz & 
Lach, 2019; Hefner et al., 2016).  Indeed, a survey of 231 smokers with severe MI who were 
patients at community mental health centers found that 22.0% reported currently using ENDS to 
quit smoking, while another 50.0% reported being interested in using ENDS as a smoking 
cessation tool (Chen et al., 2017). Taken together these data highlight the co-occurrence of 
ENDS use among smokers with MI and that use patterns may be influenced by the appeal of 
ENDS as a perceived cessation and/or harm reduction tool. Limited by data collected among the 
general population of smokers, information specific to the effectiveness of ENDS among 
smokers with MI is even sparser. 
ENDS and Smoking Cessation and Reduction for Smokers with Mental Illness  
 Some small-scale clinical studies and a secondary analysis of data from a RCT have 
investigated the effects of ENDS among smoking samples with MI in regards to smoking 
cessation and reduction. During an unblinded, uncontrolled 4-week longitudinal study conducted 
among 43 military veteran smokers with MI reporting no intention of quitting smoking in the 
next month, participants were provided with an 1.8 ohm, 4.2 volts (voltage-adjustable) ENDS 
with either 12 mg/ml or 24 mg/ml nicotine concentration liquid (participant-selected) to use ad 
lib for four weeks (Valentine et al., 2018). Significant decreases in CPD and CO levels were 






the one-month follow-up. Significant decreases in nicotine dependence scores relative to baseline 
were observed at follow-up (Valentine et al., 2018). A nine-week open trial among 12 
methadone-maintained smokers with an opioid use disorder asked participants to use a NJOY-
branded ENDS for six weeks (Stein et al., 2016). Significant reductions in CPD were observed 
across the study period with one person reporting biochemically verified 7-day point prevalence 
of smoking abstinence week 7 (Stein et al., 2016). A one-year prospective observational study 
among 14 smokers with schizophrenia asked participants to use the ENDS “Categoria” ad lib 
while reducing their cigarettes smoked (Caponnetto et al., 2013). At week 52, 50% of 
participants reported sustained 50% reduction in cigarettes smoked from baseline with 14.3% 
reported having quit smoking (Caponnetto et al., 2013). A secondary data analysis from a larger-
scale RCT comparing ENDS with and without nicotine to a nicotine patch (Bullen et al., 2013) 
evaluated condition-related effects by MI status (defined as use of medication prescribed for MI; 
O'Brien et al., 2015). Participants with MI (n=86) did not differ significantly from those without 
MI (n=571) in regards to biochemically verified cessation at six-month follow-up. Additionally, 
cessation rates among those with MI did not differ significantly by condition; however, 
participants with MI randomized to the nicotine-containing ENDS condition reported 
significantly greater reductions in CPD relative to participants with MI assigned to the nicotine 
patch (O'Brien et al., 2015). These reports suggest that ENDS may hold promise for smoking 
cessation and/or reduction among smokers with MI, but larger scale studies with greater 
methodological control and larger samples of smokers with MI are needed. 
Past research suggests that smokers with MI may use nicotine-containing cigarettes to 
manage their negative mood-related symptoms (e.g., Pomerleau et al., 1984). However, research 






serve as a substitute for cigarettes for smokers with MI. Moreover, it is not known whether, and 
to what degree, ENDS with and without nicotine may impact negative mood and stress-related 
symptoms that are characteristic of MI as well as nicotine abstinence.  
Statement of the Problem 
Cigarette smoking remains the single most preventable cause for death and disease across 
the world.  Despite only accounting for 25% of the US population, individuals with MI smoke 
40% of all US-manufactured cigarettes, develop nicotine dependence faster and to a more severe 
degree, and are less likely to quit smoking relative to smokers without MI. The self-medication 
hypothesis suggests that individuals with MI may smoke cigarettes to manage their symptoms 
via nicotine delivery. This pattern could be replaced by certain ENDS, which under certain 
conditions represent a rapid, non-cigarette-derived, nicotine delivery system. ENDS could be 
used by smokers with MI to alleviate negative mood and stress-related symptoms that increase 
during smoking cessation and/or reduction attempts. Understanding whether ENDS and their 
nicotine content operate differently among those with MI compared to those without MI as well 
as the interaction between ENDS nicotine content, changes in smoking behavior, negative mood 
and stress symptoms is critical to informing successful harm reduction efforts among this 
vulnerable population. 
The Present Study Aims and Hypotheses 
The present study used data from a RCT (NCT02342795) completed in 2018, which 
investigated the effects of a second-generation ENDS varying in nicotine concentration (0, 8, and 
36 mg/ml) relative to a plastic cigarette substitute (CIG SUB) that delivered no nicotine/aerosol 






and their associated nicotine delivery were informed by a clinical laboratory study performed by 
the same team (Hiler et al., 2017), and primary outcomes centered on condition-related changes 
in tobacco toxicant exposures and smoking behavior over the study intervention period (Cobb et 
al., 2021).  This secondary analysis focused on a subset of measures by current MI status and 
collapsed conditions by nicotine-containing status (non-nicotine=CIG SUB and 0 mg/ml vs. 
nicotine=8 mg/ml and 36 mg/ml) to increase statistical power to test nicotine-related effects. The 
specific aims were to: 
Aim 1) Test the effects of current MI status, condition, and time on changes in CPD. 
H1a: Relative to smokers without current MI, smokers with current MI were expected to report 
smaller CPD reduction over 24 weeks because past research suggests that individuals with MI 
report greater levels of nicotine dependence (Breslau et a, 1993; de Leon et al., 2002), increased 
symptoms of withdrawal (Reid & Ledgerwood, 2016), and decreased likelihood of quitting 
smoking (Cook et al., 2014). 
H1b: Between-condition differences in CPD reduction as produced by condition-related nicotine 
content in the assigned study products were expected to differ as a function of current MI status, 
with greater between-condition differences found for participants with MI than for participants 
without MI (anticipated results presented in Figure 1 below). This hypothesis is derived from 
past research suggesting smokers with MI experience more severe withdrawal symptoms when 
deprived of nicotine (Smith, Homish, et al., 2014) which in turn can be suppressed by 
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Figure 1. CPD=cigarettes per day. Hypothesized results for H1b. 
Aim 2) Test the effects of current MI status, condition, and time on changes in negative mood 
and stress measures. 
H2: Relative to the nicotine conditions, the non-nicotine conditions were expected to be 
associated with greater increases in scores on negative mood and stress measures over time 
among individuals with current MI relative to those without current MI (see Figure 2). The 
hypothesis was derived from past literature indicating that presence of an MI is linked to 
increased symptoms of nicotine abstinence and increased nicotine abstinence-related distress 
(Smith, Homish, et al., 2014). Past research suggests that smokers use nicotine to alleviate 
symptoms related to MI (e.g., Haro & Drucker-Colin, 2004a, 2004b); thus, we anticipated that 
smokers with MI would experience increases in negative mood and stress symptoms when 
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Figure 2. Hypothesized results for H2. Figure shows psychological distress (Kessler-6) scores on 
the y-axis; however, anticipated results of other negative mood and stress measures were 
expected to follow the same trend.  
 
Aim 3) Test whether changes in negative mood and stress measures mediated condition-related 
effects on CPD and whether mediation differed by current MI status. 
H3a: Changes in negative mood and stress measure scores were expected to mediate condition 
effects on CPD reduction. Individuals reporting psychological distress smoke greater CPD 
relative to those reporting no psychological distress (Kulik & Glantz, 2017) and negative affect 
is linked to increased urges of smoking (Brodbeck et al., 2014). The inability to obtain nicotine 
from study products in the non-nicotine conditions was expected to lead to smaller CPD changes 
for individuals reporting negative mood and stress symptoms.    
H3b: Mood/stress measure mediation was expected to be stronger among those with current MI. 
MI is related to increased symptoms of nicotine withdrawal and increased withdrawal-related 






symptoms (Haro & Drucker-Colin, 2004a, 2004b) and negative affect is related to increased 
smoking urges (Brodbeck et al., 2014). Thus, smokers with current MI assigned to the non-
nicotine conditions who, in addition to their current MI status reported negative mood and stress, 
were expected to report smaller CPD changes relative to smokers without current MI who 








Trial Design  
 This secondary data analysis used data derived from a two-site, four-arm, double-blind 
(for all but one condition) RCT consisting of a 24-week intervention period and a follow-up at 36 
weeks. The primary site of the trial was Virginia Commonwealth University in Richmond, VA; 
the secondary site of the trial was Penn State University College of Medicine in Hershey, PA. 
Site-specific block randomization was used to allocate participants to one of four groups, 
consisting of a CIG SUB and three ENDS differing in nicotine concentration (0, 8, and 36 
mg/ml; see Lopez et al., 2016 for detail).  
Previous findings from the parent study of this RCT included significant between-
condition differences in CPD at each post-randomization time point (Cobb et al., 2021). Relative 
to the CIG SUB condition, CPD was significantly lower in the 36 mg/ml condition at all time 
points, significantly lower for the 0 mg/ml at week 4, 8, and 16, and significantly lower for 8 
mg/ml at week 4 (Cobb et al., 2021). Significant within-condition differences also were 
observed; within all conditions, CPD significantly decreased relative to CPD reported at week 0. 
Sensitivity analyses revealed similar patterns; except for the 8 mg/ml ENDS condition at week 
12, all ENDS conditions resulted in significantly lower CPD relative to CIG SUB at all post-
randomization time points (Cobb et al., 2021). Over the intervention period, participants reduced 
their use of the study product significantly; when using intent-to-treat (missing use data assumed 
no use), little evidence of between-condition differences in study product use emerged. Study 
product use rates between week 1 and week 24 dropped from  ~87% to ~33% for CIG SUB, 
from ~85% to ~36% for 0 mg/ml, from ~88% to ~38% for 8 mg/ml, and from ~89% to ~48% for 






liquid, which was representative of cigarette-like nicotine delivery, was the most effective in 
reducing smoking behavior and associated toxicant exposure. There was some evidence of a dose 
effect for the other ENDS conditions with 0 mg/ml proving ineffective in reducing biomarkers of 
tobacco exposure. The CIG SUB condition was associated with the least CPD reduction and no 
significant changes in biomarkers of tobacco use.  
Participants 
To be eligible, participants had to be aged 21-65, use more than 9 regular or machine-
rolled filtered cigarettes per day for at least the past 12 months, and produce a CO value of at 
least 9 ppm at baseline. Eligible participants reported interest in smoking reduction but not 
quitting in the next 6 months. Specifically, eligible participants reported no serious smoking 
cessation attempts in the past month and no past-month use of any FDA-approved cessation 
medications. Individuals also had to indicate their ability to read and write in English and be able 
to provide informed consent.  
Exclusion criteria included pregnancy or nursing, inability or unwillingness to have blood 
samples taken, and known allergic reactions to vegetable glycerin or propylene glycol. Exclusion 
criteria also included past 12-month severe or unstable medical conditions including but not 
limited to heart attack and angina accompanied by high blood pressure. Moreover, participants 
suffering from significant immune system disorders such as uncontrolled HIV or AIDS, 
respiratory illnesses, or kidney or liver diseases were excluded from the parent study along with 
participants reporting medical illnesses or use of medication compromising the safety of the 
participant and/or the biomarker data collected during the trial. Individuals who reported past 6-
week surgeries involving general anesthesia were excluded. Participants who reported past-3-






medication for non-medicinal purposes per National Institute on Drug Abuse (NIDA) Quick 
Screen, were ineligible. Individuals who self-reported past-6 month inpatient treatment and/or 
uncontrolled substance abuse/mental illness were ineligible. Participants reporting hand-rolled 
cigarettes were excluded from the study, as were participants who reported past-week use of 
non-cigarette nicotine-containing products, including, but not limited to ENDS. Past-month 
ENDS use on five or more days led to exclusion as well.  
Procedures 
 All interested participants initially completed a pre-screening over the phone and were, if 
deemed potentially eligible, invited to complete an in-person screening session during which 
written informed consent was collected. If deemed eligible during the in-person screening, 
participants were prompted to engage in their typical cigarette smoking habits while tracking 
their CPD consumption for one week via paper diary. After one week, participants returned to 
the lab for their baseline visit (week 0). If week 0 was completed successfully, participants were 
randomized to one of four conditions (CIG SUB or an ENDS containing liquid with a nicotine 
concentration of 0, 8, or 36 mg/ml). Participants were asked to return to the lab for in-person 
visits during the 24-week intervention period, specifically at week 2, 4, 8, 12, 16, 20, and 24 (see 
Figure 3). Participants were prompted to use their assigned study product ad lib instead of their 
cigarettes throughout the 24-week intervention period, after which study products were no longer 
provided to participants. Participants were also prompted to reduce their cigarette smoking. 
Specifically, participants were asked to reduce their cigarette consumption by 50% during week 
0 and 2, and to reduce cigarette consumption by 75% during week 3 and 8. Participants were 
asked to continue reducing their cigarette consumption further (without specific quantification of 






and study product use (both of which participants tracked via paper diary during weeks 0-24) 
were obtained at each visit via timeline follow-back (past 7 days). Upon conclusion of the 
intervention period and ceasing of study product distribution, participants completed two 
additional follow-up visits (weeks 28 and 36). Participants who completed all visits were eligible 
to receive gift cards with a total possible monetary value of $400. Negative mood and stress 
measures were assessed during week 0, 4, 8, 16, 24, and 36. This secondary analysis focuses on 
the study intervention period visits (week 0-24) where CPD, negative mood, and stress 
symptoms were assessed concurrently (see study visits with asterisks in Figure 3). 
 
Figure 3. Study design schematic by week and condition with in-person clinic visits indicated. 
Cigarette smoking instructions that were active during a given week are indicated: 50% 
reduction (week 0-2), 75% reduction (week 3-8), continue to reduce cigarettes smoked (weeks 9-
24; i.e., until the end of the intervention period/randomization phase), and advised to cease all 
cigarette use (week 25-36; follow-up period). Asterisks (*) indicate that CPD and mood/stress 







Study Products. Study products are depicted in Figure 4. The ENDS was a 3.3-4.1 V, 1000 
mAh battery (SmokTech; Shenzhen, China), that was attached to a 1.5 ohm, dual-coil, 510-style 
cartomizer (SmokTech; Shenzhen, China) which was purchased free of liquid. AVAIL, an 
ENDS retailer in Richmond, VA, prepared the liquid solution containing 70% propylene glycol 
and 30% vegetable glycerin with nicotine concentrations of 0, 8, or 36 mg/ml in menthol and 
tobacco flavors. The accuracy of the nicotine concentration in the liquid used was confirmed by 
an independent lab. One ml of liquid was filled into each cartomizer by unblinded study staff. 
Two CIG SUB devices (QuitSmart, Inc., North Carolina, US) were given to participants in this 
condition. The CIG SUB consisted of a plastic, patented tube that resembles a tobacco cigarette 
in size, shape, and color. The plastic tube contains a porous piece of plastic and a small hole 
where the filter part and the body of the cigarette tube connect, thus creating a draw resistance 
similar to a cigarette. CIG SUB contained neither nicotine nor tobacco nor aerosol.  
 









Main outcome measures. Current MI status. During the in-person screening visit, the 
participant was handed a comprehensive list of common medical systems by body system. The 
list contained a variety of psychiatric disorders that included depression, anxiety, bipolar disorder 
I/II, schizophrenia, cognitive/other psychiatric disorders, eating disorders (anorexia nervosa, 
bulimia, binge eating disorder, night eating disorder), and alcohol and other substance use 
disorders. Participants also had the option to select “other”. If “other” was selected, participants 
were able to fill in the name of their MI into a blank text field. If a participant selected a 
condition, the researcher inquired about and recorded the date of onset and whether the condition 
was ongoing . The prevalence of current MI among participants reporting lifetime MI is 
displayed in Table 2. When categorizing current MI status, participants who self-reported 
lifetime history of a condition and also reported the condition to be ongoing were categorized as 
having current MI while all other participants were categorized as having no current MI. The no 
current MI category included individuals who reported no lifetime MI, individuals who reported 
lifetime MI but the condition to not be ongoing, and individuals who reported lifetime MI but 
had missing data for the item assessing whether a condition was ongoing.  
Table 2. Current MI among participants previously reporting lifetime MI.  
Diagnosis 
N (%) 
Lifetime MI    
   (N=230) 
Current MI 
   (N=194) 
Depression 142 (100.0) 122 (85.9) 
Anxiety 127 (100.0) 110 (86.6) 
Bipolar  32 (100.0) 28 (87.5) 
Other 26 (100.0) 23 (88.5) 
Alcohol or substance use disorder 53 (100.0) 15 (28.3) 
Schizophrenia 7 (100.0) 6 (85.7) 
Night eating disorder 4 (100.0) 3 (75.0) 






Bulimia 8 (100.0) 0 (0.0) 
Note: No lifetime diagnoses of cognitive disorders or binge eating disorder reported among 
sample. Current MI was coded as present when participants reported at least one lifetime MI and 
described at least one lifetime MI condition as ongoing. If participants had reported a lifetime MI 
and had missing data for the item assessing current MI, they were coded as not having a current 
MI.  
 
Depressive symptoms. Depressive symptoms were assessed via the Center for Epidemiologic 
Studies Depression Scale (CES-D; Radloff, 1977). Instructions stated “Below is a list of some of 
the ways you may have felt or behaved. Please indicate how often you have felt this way during 
the past week.” Items of this 20-item scale included “I was bothered by things that usually don’t 
bother me”, “I felt lonely”, “I had crying spells”, and “I felt hopeful about the future”. Answer 
options included 0= rarely or none of the time (less than 1 day), 1=some or a little of the time (1-
2 days), 2=occasionally or a moderate amount of time (3-4 days), and 3=all of the time (5-7 
days).  Four items require reverse coding. Higher scores out of the 60 total points possible 
indicate more severe depression.  
Psychological distress. Symptoms of nonspecific psychological distress were measured using 
the Kessler-6 scale (Kessler et al., 2003). Instructions for participants stated “The following 
questions ask about how you have been feeling during the past 30 days. For each question, please 
select the response that best describes how often you had this feeling”. The items listed 
symptoms including “nervous”, “hopeless”, and “so depressed that nothing could cheer you up”. 
Answer options included 0= none of the time, 1= a little of the time, 2= some of the time, 3= 
most of the time, and 4= all of the time. Scores across all items are added, totaling up to 24 






Perceived stress. Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS; 
Cohen et al., 1983). Instructions for participants stated “The questions in this scale ask you about 
your feelings and thoughts during the last month. In each case, you will be asked to indicate by 
marking how often you felt or thought a certain way.” Items included “In the last month, how 
often have you felt that things were going your way?” and “In the last month, how often have 
you felt confident about your ability to handle your personal problems?”. Response options 
ranged from 0=never to 4=very often, with four items requiring reverse coding. Higher scores 
out of the 40 total points possible indicate more severe perceived stress.  
Cigarettes per day (CPD). CPD was recorded by participants in the Daily Tobacco Use Diary 
between time points and was assessed via 7-day timeline follow-back at each in-person visit 
following screening (Sobell & Sobell, 1992). The responses of the 7-day timeline follow-back 
were averaged to provide a single estimate of CPD for each time point for Aim 1. CPD estimates 
at week 0 and week 24 were used to create a CPD reduction value for each participant by 
subtracting CPD recorded at week 24 from CPD recorded at week 0 to be used in the analyses 
for Aim 3.  
Covariates  
We examined the influence of demographic variables, baseline characteristics, and 
selected tobacco dependence-related covariates on our outcomes of interest. Unadjusted models 
(excluding covariates) constituted our primary analysis method and our sensitivity analyses 
included the following covariates.  
Demographic variables. Demographic variables included age, sex, and race/ethnicity. Age was 






the corresponding numerical value into a text field. Sex was assessed with the question “Are you 
male or female?” with participants selecting either male (1) or female (0) from a dropdown list. 
Race/ethnicity was assessed using the question “What race best describes you?” with dropdown 
list answer options including Caucasian/White, African American/Black, Asian, American 
Indian/Alaskan Native, Native Hawaiian or Pacific Islander, and Other. We also asked “Do you 
consider yourself Hispanic/Latino?” (yes, no). Those who responded with yes were asked “What 
is your Hispanic ancestry or origin?” and were prompted to select all applicable answers from a 
list of options, including, but not limited to, Mexican/Mexicano and Mexican American. 
Race/ethnicity response options were recoded into non-Hispanic White, non-Hispanic 
Black/African American, while individuals who did not self-identify with neither of the prior 
categories were classified as Other.  
Baseline characteristics. Baseline characteristics assessed included education and income. 
Education was assessed using the question “What is the highest level of school you have 
completed or the highest degree you have received?” and included answer options including less 
than 9th grade, 9th grade, 10th grade, 11th grade, 12th grade/no diploma, high school graduate, 
GED or equivalent, some college/no degree, associate degree, bachelor’s degree, master’s 
degree, professional degree, and doctoral degree. Education-related response options were 
recoded to reflect “less than college” and “some college or higher” by collapsing the initial 
answer options.  Income was assessed using the question “Which of the following income 
categories best describes your total household income last year?” with answer options ranging 
from less than $1,000 to $100,000 and over. Income was not collapsed; instead, we retained the 
original response options. Additional baseline characteristics were scores of our outcome 






Tobacco dependence-related measures. Tobacco-dependence-related factors include the Penn 
State Cigarette Dependence Scale (PSCDI; Foulds et al., 2015) and ever use of other tobacco 
products in the past. The PSCDI is a 10-item measure used to assess cigarette dependence. Items 
include “How many cigarettes per day do you usually smoke?” (0-4=0, 5-9=1, 10-14=2, 15-
19=3, 20-30=4, 31+=5), “On days that you can smoke freely, how soon after you wake up do 
you smoke your first cigarette of the day?” (within [minutes] 5=5, 6-15=4, 16-30=3, 31-60=2, 
61-120=1, 121+=0), and “Do you sometimes awaken at night to have a cigarette?” (yes=1, 
no=0). Scores range from 0 to 20, with greater scores suggesting greater cigarette-related 
dependence. Ever use of other tobacco products was assessed using the item “Have you ever 
used any other types of tobacco?” (yes, no), “What type of tobacco did you use” (cigars, 
cigarillos, little cigars, pipes, snus, chew/snuff/dip, electronic cigarettes, hookah/water pipe, 
dissolvable tobacco (lozenge, strips, or sticks)).  
Data Analysis 
Data Preparation. Our data analyses focused on data collected at five time points which 
included week 0, week 4, week 8, week 16, and week 24. Data cleaning was conducted. No 
outliers were found, and no coding errors were detected. While missing data were detected and 
will be discussed in greater detail below, we did not exclude any cases. The reason for this 
inclusion was that our analyses were conducted on an intent-to-treat (ITT) basis, meaning that 
we analyzed participant data based on the condition to which participants were randomized 
regardless of their adherence to instructions (Detry & Lewis, 2014). The purpose of ITT was to 
take a “real-world” approach to testing the effect of the intervention, as non-adherence, incorrect 
administration, and participant characteristics may impact the intervention effect (Detry & 






Restricted or residual maximum likelihood (REML) was used for Aim 1 and 2. REML is 
an approach used in order to estimate the variance components in a dataset and has been deemed 
particularly helpful when analyzing data from clinical trials which are often associated with 
unbalanced data due to drop out rates and missing data. REML utilizes all available data to 
provide a more accurate estimate when a treatment effect is available (Brown & Kempton, 
1994). For the proposed analyses of Aim 3, expectation maximization (EM) was used to impute 
missing data on all continuous outcome variables, including the negative mood and stress 
measures (Kessler-6, PSS, and CES-D) and CPD. In EM, the available data in the data set is 
assumed to provide the researcher with information that will help estimate the likely value of 
missing data points on parameters of interest (Bennett, 2001). Maximum likelihood (ML) 
methods such as EM, are used to estimate parameters in a probability distribution and to 
subsequently estimate missing data within a data set (Chen & Gupta, 2010; Myers, 2000).  
EM consists of an expectation step (E-step) and a maximization step (M-step). During the 
E-step, the EM algorithm determines the initial values to impute for missing data based on 
available data, thus producing the estimate of one’s parameter of interest (Bennett, 2001). During 
the M-step, the algorithm replaces the missing data points with the values estimated in the 
previous step and then completes maximization of likelihood with the new, complete dataset 
(Bennett, 2001). Through the M-step, new parameter estimates are obtained which are then used 
in the subsequent E-step. The repetitive process of E-step and M-step is completed when 
convergence is reached, meaning that the parameter estimates obtained during EM cycles no 
longer differ (Bennett, 2001). In EM, the data used to impute missing data should stem from 
constructs closely related to the missing data. Thus, missing CPD data was imputed using 






scores were obtained separately from available negative mood and stress data, thus creating two 
datasets that were merged upon completion of EM.  
Prior to imputing missing data, the missing data must be deemed to be “missing 
completely at random” (MCAR) or “missing at random” (MAR; Bennett, 2001). MCAR 
suggests that no relationship exists between patterns of missing data and any variables or 
available or missing data (MCAR). MAR suggests that missing data occurs due to available data 
but not due to the data that is actually missing (Bennett, 2001). NMAR refers to patterns of 
missing data that can be directly linked to the data collected, e.g., participants missing visits due 
to side effects associated with the condition to which they were assigned (Bennett, 2001). While 
both MAR and MCAR are permissible when using REML or EM, the most critical factor here is 
to determine that the missing data is not NMAR. Little’s MCAR test, which determines whether 
data is missing completely at random or not, was conducted.  
In Table 2, we outline that no differences were found in missed in-lab visits at the five 
time points by current MI status. Moreover, no differences in attrition at week 24 were observed 
by condition (p=0.15). Patterns of missing data that were found were MAR and not MNAR. 
Prior to completion of REML and EM, assumptions associated with the respective analyses were 
tested. For the linear mixed models that we used for Aim 1 and 2, the assumptions included a 
continuous outcome variable (CPD and mood and stress measures) and between-subject factors 
with more than one independent group. Also, linear mixed models assume a within-subjects 
factor with more than one group, an assumption that was met as five time points were assessed. 
Additionally, assumptions for linear mixed models that were assessed included additivity and 
linearity, absence of collinearity, homoscedasticity, normal distribution of residuals, and 






mediation analyses, assumptions of the general linear model applied; thus, normality tests, 
including skewness and kurtosis were assessed. Additionally, linearity, independence of errors, 
and homogeneity of variance were assessed. We chose not to transform data when violations of 
normality were found.  
Analyses 
 To maximize power and due to the primary interest in the effect of nicotine relative to no 
nicotine, all proposed analyses outlined below treated condition, which initially consisted of four 
levels (CIG SUB and ENDS with varying liquid nicotine concentrations) as two levels differing 
in nicotine-containing status (non-nicotine-containing conditions and nicotine-containing 
conditions). Hence, the four conditions were collapsed into two condition groupings. Upon 
completion of data cleaning, descriptive and bivariate analyses including independent group t-
tests and chi-square tests were used to characterize the sample in regards to demographics, 
cigarette smoking history, baseline CPD, nicotine dependence, current MI status, and mood and 
stress symptoms across the two collapsed conditions. Clinically relevant cutoff scores for 
negative mood and stress measures also were used to characterize the sample.  
 Aim 1 Analysis. For Aim 1 analyses, linear mixed models were used to investigate the 
relationship of MI status and/or condition and changes in CPD over 24 weeks as indexed by 
mean differences. For Aim 1a and Aim 1b, subject-specific effects represented the random 
factor. For Aim 1a and Aim 1b, one mixed linear model was conducted with the fixed factors of 
current MI (two levels; yes, no), condition (two levels; non-nicotine, nicotine), and time (five 
levels; week 0, 4, 8, 16, and 24). Main effects and interactions were assessed, with the interaction 






H1b. Significant main effects and/or interactions were explored with t-tests using a Bonferroni 
correction with which we assessed mean differences between non-nicotine-containing and 
nicotine-containing conditions and within condition groupings (relative to week 0). 
Aim 2 Analysis. Each outcome variable (scores on negative mood and stress measures) 
was assessed separately using linear mixed models as in Aim 1 with the same fixed and random 
factors.  Main effects and interactions were assessed, with the interaction of MI status (two 
levels; yes, no) x conditions (two levels; non-nicotine and nicotine) x time (five levels: week 0, 
4, 8, 16, 24) addressing H2. Significant main effects and/or interactions were explored with t-
tests using a Bonferroni correction with which we assessed mean differences between non-
nicotine-containing and nicotine-containing conditions and within condition groupings (relative 
to week 0). 
Aim 3 Analysis. The third aim tested whether changes in negative mood and stress 
scores would mediate condition-related effects on CPD and whether the mediation was 
moderated by current MI status. After performing EM, we created an average for all three 
negative mood and stress measures by adding the scores at each of the five time points together 
and then dividing the total by five. We then z-score transformed the newly created averages for 
each negative mood and stress measure. After creating the z-scores for each variable, we created 
two composite score variables. First, we added the CES-D, Kessler-6, and PSS z-scores together 
and divided the total by three, thus creating the composite variable “negative mood and stress”. 
Second, we added only the CES-D and Kessler-6 z-scores together and divided the total by two, 
thus creating the composite variable “negative mood”. After performing EM, to estimate change 
in the CPD over the intervention period, we created a difference score for each participant using 






Mediation models also included condition (two levels; non-nicotine, nicotine) and/or current MI 
status (2 levels; yes, no). All predictor variables were mean-centered except for the already z-
score transformed negative mood and stress variables. Categorical predictors were, when 
applicable, transformed to contain an assigned value of 0 for one of the categories. Despite past 
research suggesting a correlation between the negative mood and stress variables of interest 
(Cohen et al., 1983), we ran five separate mediation models in PROCESS macro (Hayes, 2014) 
to assess direct and indirect effects utilizing 5,000 bootstrap samples. The five mediation models 
included one mediation model for each of the composite variables and one mediation model for 
each of the z-score transformed negative mood and stress variables. For each of the five 
mediation models, we specified that condition would lead to changes in mood and stress 
symptoms, which in turn would lead to changes in CPD (see Figure 5).  
 
Figure 5. Mediation model. Mood and stress symptoms (scores derived from CES-D, Kessler-6, 
and PSS) mediating the relationship between condition (non-nicotine-containing, nicotine-
containing) and CPD reduction.  
 
The second hypothesis of Aim 3 predicted that the mediation of negative mood and stress 
measure mediation would be stronger among individuals with current MI (see Figure 6). We 
planned to use PROCESS Macro model 7 to expand the previously described mediation into 
moderated mediations, with MI status (yes, no) serving as the moderator between condition 







Figure 6. Moderated mediation model. Mood and stress symptoms (as indexed by scores on the 
CES-D, Kessler-6, and PSS) mediating the relationship between condition (non-nicotine and 
nicotine) and CPD reduction, with current MI status moderating the direct effects.  
 
 Sensitivity Analyses. Sensitivity analyses were conducted in order to determine whether 
previously unassessed variables would alter the results or whether results would remain robust 
(Schneeweiss, 2006). Each analysis was run first without controlling for covariates, and then 
again while controlling for relevant covariates, in order to determine whether outcomes had 
changed based on potentially confounding variables. For all three Aims, we included 
demographics (e.g., age, sex, race/ethnicity) and site as well as additional relevant variables that 
we expected to influence the outcomes, such as the baseline scores of the respective outcome 
assessed. In the sensitivity analyses for Aim 1 we controlled for baseline Kessler-6 scores but 
chose not to control for baseline CES-D scores, as CES-D and Kessler-6 correlated highly with 
one another. Additionally, because the CES-D measures depressive symptoms we anticipated 
there to be overlap with MI given the high prevalence of depression diagnoses in our sample. For 
the analyses associated with H1a, H1b and H2, we controlled for baseline cigarette dependence 
(Penn State Cigarette Dependence Scale and ever use of other-tobacco products, the latter of 






use, as all participants who reported past 7-day use of other tobacco products were excluded at 
baseline. For each of the outcomes assessed in H2, we controlled for each measure’s respective 
baseline score. We did not control for Kessler-6 baseline scores when assessing CES-D scores 
and vice versa due to the reasons outlined above for H1a and H1b; however, we controlled for 
PSS scores at baseline for the two negative mood outcomes. When investigating the H2 outcome 
PSS, we controlled for Kessler-6 scores at baseline. For H3a and H3b, we also controlled for 
baseline CPD.  
Aim 1 and 2 Power Analysis. We considered running a power analysis for our proposed 
linear mixed models with our selected fixed factors, including our within-subjects factor (time) 
and our between-subjects factors (condition and current MI status) for each of our outcomes 
(CPD, Kessler-6, CES-D, and PSS). However, the complexity of the proposed models and 
interactions of interest, challenged this task. As an alternative, we used the available data 
(untransformed, without covariate adjustment or EM) at week 4 and 24 to estimate the observed 
power to detect differences by condition and MI status using a between-subjects analysis of 
variance for each time point separately (see Table 3). Observed power for these differences 
between conditions varied by time point and by outcome assessed, but overall higher power was 
noted for main effects of condition and MI status with lower power for the interaction between 
the two factors (as low as <0.06). These estimates supported approaches to increase power by 
simplifying the models assessed by collapsing the conditions by nicotine-containing status. 
Power estimates were expected to be improved by our use of REML/EM to impute missing data.  
Additionally, a power analysis was conducted using G*Power software (Faul et al., 2009) to 






Assuming a fairly small effect size of 0.15, 351 participants should be sufficient to detect an 
effect (power > 0.8, alpha < 0.05).  
 
Table 3. Observed power for outcomes across week 0 and week 24  
 Week 0 Week 24 
Variables assessed   
CPD   
     MI status 0.054 0.471 
     Condition 0.912 0.923 
     MI status*condition 0.075 0.105 
CES-D   
     MI status 1.000 0.998 
     Condition 0.734 0.119 
     MI status*condition 0.100 0.202 
PSS   
     MI status 0.589 0.790 
     Condition 0.108 0.072 
     MI status*condition 0.050 0.066 
Kessler-6   
     MI status 0.997 1.000 
     Condition 0.505 0.835 
     MI status*condition 0.050 0.535 
Note. CPD=cigarettes per day; CES-D=Center for Epidemiologic Studies Depression Scale; 
PSS=Perceived Stress Scale. Asterisks (*) denote an interaction effect between the two factors 
MI status and condition.     
Results 
Current sample 
The present analyses utilize data derived from 520 individuals that were randomized to 
four conditions. Across the sample, overall attrition at week 24 was 36% (188/520) and did not 
differ significantly by condition (p=0.15): 43% (56/130) for 0 mg/ml, 38% (49/130) for 8 mg/ml, 
34% (44/130) for 36 mg/ml and 30% for CS (39/130). Relative to participants who completed 
the study, the 188 participants who did not attend the week 24 visit were about four years 






initiation by about 1 year (p=0.003), and more cigarette dependent (p=0.01). Non-completers had 
higher forced vital capacity as measured by PFT at baseline relative to completers (p=0.04). For 
the percentage of missed visits across time points by condition, please refer to Table 4. We found 
no significant differences between the percentages of missing data between conditions collapsed 
by nicotine-containing status (see Table 4). Missing data for the measures of interest (i.e., CPD, 
CES-D, Kessler-6, and PSS) are depicted in Table 5.  









Week 0, n (%) 0 (0.0) 0 (0.0) 0 (0.0) N/A 
Week 4, n (%) 49 (18.8) 38 (14.6) 87 (16.7) 0.196 
Week 8, n (%) 81 (31.2) 73 (28.1) 154 (29.6) 0.442 
Week 16, n (%) 104 (40.0) 98 (37.7) 202 (38.8) 0.589 
Week 24, n (%) 100 (38.5) 106 (40.8) 206 (39.6) 0.591 
Note. p-values were calculated using Pearson’s chi-square test.  
 
Table 5. Percentage of missing data on mood and stress measures across time points 
 
Measure Week 0 Week 4 Week 8 Week 16 Week 24 
CPD, n (%) 0 (0.0) 88 (16.9) 154 (29.6) 201 (38.7) 206 (39.6) 
CES-D, n (%) 0 (0.0) 131 (25.2) 172 (33.1) 221 (42.5)  222 (42.7) 
Kessler-6, n (%) 14 (2.7) 102 (19.6) 162 (31.2) 207 (39.8) 212 (40.8) 
PSS, n (%) 0 (0.0) 99 (19.0) 163 (31.3) 213 (41.0) 221 (42.5) 
Note. CPD=cigarettes per day, CES-D=Center for Epidemiologic Studies Depression Scale, 
PSS=Perceived Stress Scale.  
 
 
Baseline characteristics including demographic data and baseline negative mood and 
stress scores across the sample and by condition grouping are depicted in Table 6. As was 






the four randomized conditions (Cobb et al., 2021), no significant differences were observed by 
condition grouping for any measure examined. Across the sample, participants were about 46 
years old on average and were mostly women (58.8%). The majority of participants identified as 
White (67.3%). Almost 60% reported having completed at least some college education. 
Participants reported smoking an average CPD of 19. For the CES-D at baseline, the average 
score fell below the clinical cutoff of 16 (mean; M=12.3, standard deviation; SD=9.8; Weissman 
et al., 1977). Across the sample, almost one third (27.5%) met or exceeded the CES-D clinical 
cutoff. For the Kessler-6, the average scores were well below the clinical cutoff (score of ≥13; 
M=4.9, SD=4.2; Kessler et al., 2003). Across the entire sample, 8.1% had a score that met or 
exceeded the clinical cutoff for the Kessler-6. Perceived stress at baseline was moderate, with 
average scores falling below the cutoff for severe perceived stress (scores of ≥27; M=19.9, 
SD=4.1). Across the sample, 37.3% of participants reported current MI at baseline. The most 
prevalent conditions were depression (23.5%) and anxiety (21.2%), followed by bipolar disorder 
(5.4%). No significant differences in the distribution of current MI status or specific MI 
diagnoses were observed by condition grouping (see Table 7).  
 
Table 6. Baseline characteristics by condition grouping 
 
 
Baseline characteristics by condition  
Baseline characteristics by condition  
 








Age    0.537 
          Available N 260 260 520  
          M (SD) 45.9 (11.9) 46.5 (11.4) 46.2 (11.6)  
Site of recruitment    1.000 
          Available N 260 260 520  
          Richmond, VA, n (%) 100 (38.5) 100 (38.5) 200 (38.5)  
          Hershey, PA, n (%) 160 (61.5) 160 (61.5) 320 (61.5)  
Sex    0.285 
          Available N 260 260 520  






          Female, n (%) 101 (38.8) 113 (43.5) 306 (58.8)  
Race/ethnicity    0.977 
Available N 260 260 520  
White NH, n (%) 175 (67.3) 175 (67.3) 350 (67.3)  
African American/Black NH, n (%) 72 (27.7) 73 (28.1) 145 (27.9)  
Other, n (%) 13 (5.0) 12 (4.6) 25 (4.8)  
Education    0.211 
          Available N 260 260 520  
          Less than college, n (%) 112 (43.1) 98 (37.7) 210 (40.4)  
          Some college or higher, n (%) 148 (56.9) 162 (62.3) 310 (59.6)  
Income     0.242 
           Available N 255 255 510  
          Less than $10,000 58 (22.7) 50 (19.6) 108 (21.2)  
          $10,000-$39,999 99 (38.8) 94 (36.9) 193 (37.8)  
          $40,000-$69,999 47 (18.4) 54 (21.2) 101 (19.8)  
          $70,000-$99,999 34 (13.3) 33 (12.9) 67 (13.1)  
          $100,000 or more 17 (6.7) 24 (9.4) 41 (8.0)  
CPD (7-day average)    0.970 
             Available N 260 260 520  
             M (SD)  18.6 (7.8) 18.6 (7.7) 18.6 (7.7)  
Penn State Cigarette Dependence Scale 
Score 
   0.165 
          Available N 247 248 495  
          M (SD) 13.6 (2.8) 13.2 (3.1) 13.4 (3.0)  
Ever use of other tobacco product    1.000 
          Available N 260 260 520  
          Never use of other tobacco, n (%) 124 (47.7) 124 (47.7) 248 (47.7)  
          Ever use of other tobacco, n (%) 136  (52.3) 136 (52.3) 272 (52.3)  
CES-D    0.265 
           Available N 233  241 474  
           M (SD)            12.9 (9.9) 11.9 (9.7) 12.3 (9.8)  
Kessler-6    0.967 
           Available N 254 252 506  
           M (SD) 4.9 (4.3) 4.9 (4.1) 4.9 (4.2)  
PSS    0.227 
           Available N 250 255  505  
           M (SD) 19.9 (4.4) 19.8 (3.8) 19.9 (4.1)  
   Current mental illness (MI)    0.147 
           Available N 260 260 520  
           No current MI, n (%) 155 (59.6) 171 (65.8) 326 (62.7)  
           Current MI, n (%) 105 (40.4) 89 (34.2) 194 (37.3)  
  Clinical cutoff CES-D    0.492 
           Available N 260 260 520  
           CES-D cutoff not met, N (%) 185 (71.2) 192 (73.8) 377 (72.5)  






  Clinical cutoff Kessler-6    0.748 
           Available N 260 260 520  
           K6 cutoff not met, N (%) 240 (92.3) 238 (91.5) 478 (91.9)  
           K6 cutoff met, N (%) 20 (7.7) 22 (8.5) 42 (8.1)  
  Clinical cutoff PSS     
           Available N    0.648 
           PSS cutoff not met, N (%) 249 (95.8) 251 (96.5) 500 (96.2)  
           PSS cutoff met, N (%) 11 (4.2) 9 (3.5) 20 (3.8)  
 
Note: M=Mean, SD= standard deviation, NH=non-Hispanic, CPD=cigarettes per day, CES-
D=Center for Epidemiologic Studies Depression Scale, PSS=perceived stress scale. p-values 
were calculated using independent samples t-tests for continuous variables and Pearson’s chi-
square tests for categorical variables.  
 
 
Table 7. Current mental illness diagnoses by condition grouping 










Any current MI 105 (40.4) 
ffgffgg((((((((
((40.4) 
89 (34.2) 194 (37.3) 0.147 
Depression 63 (24.2) 59 (22.7) 122 (23.5) 0.679 
Anxiety 63 (24.2) 47 (18.1) 110 (21.2) 0.086 
Bipolar  14 (5.4) 14 (5.4) 28 (5.4) 1.000 
Other 1  (5.4) 9 (3.5) 23 (4.4) 0.286 
Alcohol or other substance use disorder 5 (1.9) 10 (3.8) 15 (2.9) 0.190 
Schizophrenia 3 (1.2) 3 (1.2) 6 (1.2) 1.000* 
Night eating disorder 3 (1.2) 0 (0.0) 3 (0.6) 0.249* 
Anorexia nervosa 2 (0.8) 1 (0.4) 3 (0.6) 1.000* 
Note: Asterisks (*) indicates that Fisher’s exact test was used. All other p-values were calculated 
using Pearson’s chi-square test. While binge eating disorder was assessed, no participants 
reported current binge eating disorder.  
 
Differences by MI status 
Baseline characteristics by current MI status are displayed in Table 8. Participants with 
MI were significantly more likely to be men (68%) and White NH (80.4%), both p=0.001. 
Participants who reported current MI were more likely to be enrolled in the study at the data 






D scores were significantly higher among those with current MI (M=15.8, SD=10.7) compared to 
those without (M=10.4, SD=8.7; p=0.001). This same pattern was observed for the Kessler-6 
scale (M=6.7, SD=4.6 vs. M=3.9, SD=3.5) and the PSS (M=20.9, SD=3.9 vs. M=19.3, SD=4.1; 
both p=0.001). Smokers with MI were also significantly more likely to meet the clinical cutoff 
for each of the negative mood and stress measures than participants without MI, with 39.2% 
meeting the clinical cutoff score for the CES-D (vs. 20.6%), 14.9% meeting the clinical cutoff 
score for the Kessler-6 (vs. 4.0%), and 6.7% meeting the clinical cutoff score of the PSS (vs. 
2.1%), all ps<0.01. When comparing percentages of missed visits by MI status, there were no 
significant differences between those who reported current MI and no current MI (see Table 9), 
suggesting that participants in both groups were equally likely to miss visits throughout the 
study.  
 









Age     0.622 
          Available N 326 194 520  
          M (SD) 46.4 (12.0) 45.9 (11.1) 46.2 (11.6)  
Sex          0.001 
         Available N 326 194 520  
         Male, n (%) 174 (53.4) 132 (68.0) 214 (41.2)  
         Female, n (%) 152 (46.6) 62 (32.0) 306 (58.8)  
Race/ethnicity   520 0.001 
Available N 326 194 520  
White NH, n (%) 194 (59.5) 156 (80.4) 350 (67.3)  
African American/Black NH, n (%) 116 (35.6) 29 (14.9) 145 (27.9)  
Other, n (%) 16 (4.9) 9 (4.6) 25 (4.8)  
Education    0.323 
          Available N 326 194 520  
          Less than college, n (%) 137 (42.0) 73 (37.6) 210 (40.4)  
          Some college or higher, n (%) 189 (58.0) 121 (62.4) 310 (59.6)  
Income    0.662 






          Less than $10,000 67 (20.9) 41 (21.7) 108 (21.2)  
          $10,000-$39,999 119 (37.1) 74 (39.2) 193 (37.8)  
          $40,000-$69,999 65 (20.2) 36 (19.0) 101 (19.8)  
          $70,000-$99,999 40 (12.5) 27 (14.3) 67 (13.1)  
          $100,000 or more 30 (9.3) 11 (5.8) 41 (8.0)  
Site 
 
   <0.001 
          Available N 326 194 520  
           Penn State University  174 (53.4) 146 (75.3) 320 (61.5)  
           Virginia Commonwealth University 152 (46.6) 48 (24.7) 200 (38.5)  
Cigarettes/day (7-day average)    0.608 
            Available N 326 194 520  
            M (SD) 18.5 (7.7) 18.8 (7.9) 18.6 (7.7)  
Penn State Cigarette Dependence Scale 
Score 
   0.017 
         Available N 313 182 495  
         M (SD) 13.2 (2.9) 13.8 (3.0) 13.4 (3.0)  
Ever use of other tobacco products    0.947 
         Available N 326 194 520  
         Never use of other tobacco, n (%) 155 (47.5) 93 (47.9) 248 (47.7)  
         Ever use of other tobacco, n (%) 171 (52.5) 101 (52.1) 272 (52.3)  
CES-D    0.001 
          Available N 302 172 474  
          M (SD) 10.4 (8.7) 15.8 (10.7) 12.3 (9.8)  
Kessler-6    0.001 
           Available N 316 190 506  
           M (SD) 3.9 (3.5) 6.7 (4.6) 4.9 (4.2)  
PSS    0.001 
           Available N 320 185 505  
           M (SD) 19.3 (4.1) 20.9 (3.9) 19.9 (4.1)  
  Clinical cutoff CES-D    0.001 
           Available N 326 194 520  
           CES-D cutoff not met, N (%) 259 (79.4) 118 (60.8) 377 (72.5)  
           CES-D cutoff met, N (%) 67 (20.6) 76 (39.2) 143 (27.5)  
  Clinical cutoff Kessler-6    0.001 
           Available N 326 194 520  
           K6 cutoff not met, N (%) 313 (96.0) 165 (85.1) 478 (91.9)  
           K6 cutoff met, N (%) 13 (4.0) 29 (14.9) 42 (8.1)  
  Clinical cutoff PSS    0.009 
           Available N 326 194 520  
           PSS cutoff not met, N (%) 319 (97.9) 181 (93.3) 500 (96.2)  
           PSS cutoff met, N (%) 7 (2.1) 13 (6.7) 20 (3.8)  
Note: Bold p-values indicate significant differences (p<0.05). p-values were calculated using 
independent samples t-tests for continuous variables and Pearson’s chi-square tests for 
categorical variables. NH=non-Hispanic; CPD=cigarettes per day, CES-D=Center for 

















Week 0, n (%) 0 (0.0) 0 (0.0) 0 (0.0) N/A 
Week 4, n (%) 51 (15.6) 36 (18.6) 87 (16.7) 0.389 
Week 8, n (%)  94 (28.8) 60 (30.9) 154 (29.6) 0.613 
Week 16, n (%) 120 (36.8) 82 (42.3) 202 (38.8) 0.217 
Week 24, n (%) 126 (38.7) 80 (41.2) 206 (39.6) 0.560 
Note: p-values were calculated using Pearson’s chi-square test. 
Aim 1 and 2 
 Data from all available data points from the 520 participants were used for the linear 
mixed model analyses of Aim 1 and 2. For linear mixed model results unadjusted and adjusted 
for covariates, please refer to Table 10. Results for covariates used in the different models are 







Table 10. Statistical results summary for Aim 1 and 2 linear mixed models without and with covariate adjustment. 
Note.  Bold p-values indicate significance (p<0.05). CPD=Cigarettes per day; CES-D=Center for Epidemiologic Studies Depression Scale; PSS=Perceived Stress Scale. Results for 
MI x Time x Condition are not included due to the lack of significant interactions noted.  
a df MI = (1, 498.91), df TIME = (4, 1429.68), df CONDITION = (1, 498.91); df MIxTIME= (4, 1429.68); df MIxCONDITION = (1, 498.91); df TIMExCONDITION = (4, 1429.68) 
b df MI = (1, 493.15), df TIME = (4 ,1411.24), df CONDITION = (1,501.54); df MIxTIME= (4, 1412.37); df MIxCONDITION = (1, 503.35); df TIMExCONDITION = (4, 1412.00) 
c df MI = (1,521.27), df TIME = (4, 1336.49), df CONDITION = (1,521.27); df MIxTIME= (4,1336.49); df MIxCONDITION = (1,521.27); df TIMExCONDITION = (4,1336.49) 
d df MI = (1, 464.98), df TIME = (4, 1305.90), df CONDITION = (1,474.10); df MIxTIME= (4, 1307.01); df MIxCONDITION = (1, 472.60); df TIMExCONDITION = (4, 1307.12) 
e df MI = (1,532.79), df TIME = (4,1463.92), df CONDITION = (1,532.79); df MIxTIME= (4,1463.92); df MIxCONDITION = (1,532.79); df TIMExCONDITION = (4,1463.92) 
f df MI = (1, 495.23), df TIME = (4, 1442.65), df CONDITION = (1,503.15); df MIxTIME= (4, 1443.19); df MIxCONDITION = (1, 503.60); df TIMExCONDITION = (4, 1443.19) 
g df MI = (1,530.52), df TIME = (4,1455.20), df CONDITION = (1,530.52); df MIxTIME= (4,1455.20); df MIxCONDITION = (1,530.52); df TIMExCONDITION = (4,1455.20) 
h df MI = (1, 499.54), df TIME = (4,1417.54), df CONDITION = (1,510.00); df MIxTIME= (4, 1418.37); df MIxCONDITION = (1, 510.79); df TIMExCONDITION = (4, 1418.27) 
 
  




 F p F p F p F p F p F p 
CPDa 2.70 0.101 355.17 <0.001 7.64 0.006 2.36 0.051 0.03 0.875 5.65 <0.001 
CPD-adjustedb 0.09 0.763 342.18 <0.001 20.97 <0.001 2.29 0.057 0.10 0.757 5.73 <0.001 
             
CES-Dc 52.71 <0.001 1.011 0.400 1.04 0.308 1.93 0.104 0.09 0.761 2.39 0.049 
CES-D-adjustedd 15.66 <0.001 0.57 0.688 0.03 0.870 3.08 0.015 2.24 0.135 1.78 0.130 
             
Kessler-6e 57.72 <0.001 3.46 0.008 3.64 0.057 1.67 0.154 2.56 0.108 2.19 0.067 
Kessler-6-adjustedf 13.35 <0.001 3.24 0.012 5.17 0.023 2.64 0.032 2.54 0.112 1.82 0.122 
             
PSSg 16.84 <0.001 10.66 <0.001 0.22 0.641 0.70 0.590 0.29 0.588 0.79 0.532 























Note. Bold p-values indicate significance (p<0.05). CPD=cigarettes per day; CES-D=Center for Epidemiologic Studies Depression Scale;  
PSS=Perceived Stress Scale; PSCDI=Penn State Cigarette Dependence Index. Blank cells indicate that particular covariate was not controlled for in a 
specific model.  
a df CPD = (1, 489.92), df CES-D= (1,467.68), df KESSLER-6 = (1, 498.98); df PSS= (1, 499.53)  
b df CPD = (1, 491.58), df CES-D= (1, 463.34), df KESSLER-6 = (1, 501.24); df PSS= (1, 500.16) 
c df CPD = (2, 491.43), df CES-D= (2, 467.01), df KESSLER-6 = (2, 505.39); df PSS= (2, 501.50) 
d df CPD = (1, 479.89), df CES-D= (1, 448.71), df KESSLER-6 = (1, 486.88); df PSS= (1, 487.33) 
e df CPD = (1, 545.40), df CES-D= not included, df KESSLER-6 = not included; df PSS= not included 
f df CPD = not included, df CES-D= (1, 458.53), df KESSLER-6 = not included; df PSS= not included 
g df CPD = (1, 504.21), df CES-D= not included, df KESSLER-6 = (1, 510.79); df PSS= (1,510.350) 
h df CPD = (1, 498.47), df CES-D= (1, 469.71), df KESSLER-6 = (1, 500.02); df PSS= (1,485.017) 
i df CPD = (1, 486.67), df CES-D= (1, 445.23), df KESSLER-6 = (1,477.08); df PSS= (1,479.372) 




 CPD CES-D Kessler-6 PSS 
 F p F p F p F p 
Agea 0.09 0.760 3.06 0.081 0.10 0.758 0.03 0.874 
Sexb 0.43 0.511 0.00 0.983 0.69 0.405 6.42 0.012 
Race/ethnicityc 3.70 0.025 0.41 0.661 0.31 0.734 6.90 0.001 
Sited 4.93 0.027 0.52 0.472 0.43 0.513 2.39 0.123 
CPD at baselinee 575.89 <0.001 - - - - - - 
CES-D at baselinef - - 971.48 <0.001 - - - - 
Kessler-6 at baselineg 1.95 0.163 - - 542.86 <0.001 6.69 0.010 
PSS at baselineh 0.26 0.609 2.97 0.085 11.84 0.001 1.73 0.189 
PSCDI at baselinei 1.04 0.308 0.20 0.655 2.35 0.126 1.33 0.250 
Other tobacco use at baselinej 0.02 0.903 0.65 0.421 0.23 0.630 1.73 0.189 
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Cigarettes per day. The hypothesis that smokers with current MI would report smaller 
reductions in CPD over 24 weeks than smokers without current MI (H1a) was partially 
supported. The interaction of MI status and time was not significant, F(4,1429.68)=2.36, 
p=0.051. However, due to the interaction approaching significance (p=0.051), post-hoc tests 
were performed (see Figure 7). Significant between-group differences were observed at week 16, 
where smokers without current MI reported significantly fewer CPD (estimated marginal means, 
EMM=8.60, 95% confidence interval; 95% CI =7.71,9.50) relative to smokers with current MI 
(EMM=10.48, 95% CI =9.30,11,67; p=0.013). Significant differences were also observed at 
week 24, where smokers without current MI reported significantly fewer CPD (EMM=8.33, 95% 
CI =7.43,9.23) relative to smokers with current MI (EMM=9.84, 95% CI=8.65,11.02; p=0.047). 
To test within-condition differences (i.e., relative to week 0), post hoc tests were conducted with 
a Bonferroni corrected alpha of 0.0125 per test. Relative to week 0 (EMM=18.45, 95% CI 
=17.65,19.25), smokers without mental illness significantly reduced their reported CPD at week 
4 (EMM=10.80, 95% CI=9.96,11.64), week 8 (EMM=9.98, 95% CI=9.11,10.85), week 16 
(EMM=8.60, 95% CI =7.71,9.50), and week 24 (EMM=8.33, 95% CI=7.42,9.23; all ps<0.001). 
Similarly for smokers with MI significant reductions in CPD relative to week 0 (EMM= 18.82, 
95% CI =17.78,19.85) were observed at week 4 (EMM= 11.07, 95% CI=9.97,12.17), week 8 
(EMM=10.93, 95% CI=9.80,12.07), week 16 (EMM=10.48, 95% CI=9.30,11.67) and week 24 







Figure 7. CPD over time by current MI status. CPD=cigarettes per day. Analyses are unadjusted 
for covariates and represent estimated marginal means with 95% CI (lower limit, upper limit). 
Filled symbols indicate a significant difference relative to week 0 within that group (Bonferroni 
correction α=0.0125; four comparisons with week 0 for each group). One between-group 
comparison was done at each time point (no Bonferroni correction); asterisks (*) indicate a 
significant (p<0.05) difference between participants without and with current MI at that time 
point. 
 
The hypothesis that between-condition differences in CPD reduction as produced by 
condition-related nicotine content in the assigned study products would differ as a function of 
current MI status, with greater between-condition differences found for participants with MI than 
for participants without MI (H1b) was not supported; the three-way interaction between current 
MI, time, and condition was not significant, F(4,1429.68)=0.32, p=0.864.  
However, a significant interaction between time and condition was observed, 
F(4,1429.7)=5.65, p<0.001. Post hoc analyses (see Figure 8) revealed significant differences 
between conditions at weeks 4, 8, 16, and 24, with smokers randomized to the non-nicotine 
conditions reporting significantly greater CPD relative to those in the nicotine conditions (week 
24 EMM=10.30, 95% CI=9.30,11.33 vs. EMM=7.86, 95% CI=6.79,8.94; p=0.001). Within-






(EMM=18.62, 95% CI=17.71,19.53), smokers reported significantly fewer CPD at week 4 
(EMM=11.96, 95% CI=11.0,12.92), week 8 (EMM=11.52, 95% CI=10.51,12.52), week 16 
(EMM=10.44, 95% CI=9.40,11.48), and week 24 (EMM=10.30, 95% CI=9.27,11.33), all ps 
<0.0125. Within the nicotine conditions, relative to CPD at week 0 (EMM= 18.65, 95% 
CI=17.71,19.59), smokers reported significantly fewer CPD at week 4 (EMM=9.91, 95% 
CI=8.92,10.90), week 8 (EMM=9.40, 95% CI=8.38,10.42), week 16 (EMM=8.64, 95% 
CI=7.58,9.71), and week 24 (EMM=7.86, 95% CI=6.79,8.94; all ps<0.0125).  
 
Figure 8. CPD over time by non-nicotine and nicotine conditions. CPD=Cigarettes per day. 
Analyses are unadjusted for covariates and represent estimated marginal means with 95% CI 
(lower limit, upper limit). Filled symbols indicate a significant difference relative to week 0 
within that group (Bonferroni correction p=0.0125; four comparisons with week 0 were done for 
each group). One between-group comparison was done at each time point (no Bonferroni 
correction); asterisks (*) indicate a significant (p<0.05) difference between participants in the 
non-nicotine and nicotine conditions at that time point. 
 
Cigarettes per day: Sensitivity analysis. When controlling for demographics, site, CPD 
score at week 0, Kessler-6 score at week 0, PSS at week 0, other tobacco use, and PSCDI at 
week 0, the hypothesis that smokers with current MI would report smaller CPD reduction over 






current MI status was not significant, F(4,1412.37)=2.29, p=0.057. However, because the 
interaction between MI and time was approaching significance, we conducted post hoc tests to 
investigate within-group and between-group differences (see Figure 9). No significant between-
group differences were found at any time points (all ps>0.05). As in the unadjusted analysis, we 
used a Bonferroni adjusted alpha level of 0.0125 to investigate within-group differences. 
Relative to week 0 CPD (EMM=17.74, 95% CI=16.96,18.51), participants without current MI 
reported smoking significantly fewer CPD at week 4 (EMM=10.34, 95% CI=9.54,11.15), week 8 
(EMM=9.45, 95% CI=8.60,10.29), week 16 (EMM=8.00, 95% CI=7.13,8.87), and week 24 
(EMM=7.69, 95% CI=6.82,8.56; all ps<0.001). Similarly, for participants with current MI, 
participants reported significantly fewer CPD at week 4 (EMM=9.77, 95% CI=8.74,10.79), week 
8 (EMM=9.42, 95% CI=8.35,10.49), week 16 (EMM=9.12, 95% CI=8.00,10.24), and week 24 
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Figure 9. CPD over time by current MI status with covariate adjustment. CPD=cigarettes per 
day. Covariates included: sex, age, race/ethnicity, site, week 0 CPD, week 0 Kessler-6 score, 
week 0 PSS score, week 0 Penn State Cigarette Dependence Index score. Estimated marginal 






difference relative to week 0 within that group (Bonferroni correction p=0.0125; four 
comparisons with week 0 were done for each group). No significant between-group comparisons 
were observed (all ps>0.05). 
 
When controlling for covariates, as was observed in the unadjusted analysis, the three-
way interaction between current MI status, time, and condition was not significant, 
F(4,1411.67)= 0.36, p=0.839. However, a significant interaction of time and condition for CPD 
when adjusted for covariates was observed, F(4,1412.0)=5.730, p<0.001 (see Figure 10). At 
week 4, 8, 16, and 24, smokers in the non-nicotine condition reported significantly greater CPD 
than the non-nicotine condition (week 24 EMM=9.27, 95% CI=8.30,10.23 vs. EMM=6.67, 95% 
CI=5.66,7.69; p<0.001). Using the same Bonferroni adjusted alpha as in previous models, for the 
non-nicotine conditions significant within-groups differences in CPD relative to week 0 CPD  
(EMM=17.54, 95% CI=16.69,18.38) were observed at week 4 (EMM=11.19, 95% 
CI=10.30,12.07), week 8 (EMM=10.40, 95% CI=9.46,11.34), week 16 (EMM=9.55, 95% 
CI=8.58,10.51), and week 24 (EMM=9.27, 95% CI=8.30,10.23), all ps<0.001. For the nicotine 
condition, significant within-groups differences in CPD relative to week 0 CPD (EMM=17.49, 
95% CI=16.62,18.37) were observed at week 4 (EMM=8.92, 95% CI=8.00,9.85), week 8 
(EMM=8.46, 95% CI=7.50,9.42), week 16 (EMM=7.58, 95% CI=8.58,10.51), and week 24 







Figure 10. CPD over time by condition grouping. CPD=cigarettes per day. Adjusted model 
covariates included: sex, age, race/ethnicity, site, week 0 cigarettes per day, week 0 Kessler-6 
score, week 0 perceived stress score, week 0 Penn State Cigarette Dependence Index score, and 
other tobacco use. Estimated marginal means with 95% CI (lower limit, upper limit) are 
displayed. Filled symbols indicate a significant difference relative to week 0 within that group 
(Bonferroni correction p=0.0125; four comparisons with week 0 were done for each group). One 
between-group comparison was done at each time point (no Bonferroni correction); asterisks (*) 
indicate a significant difference (p<0.05) between participants in the non-nicotine and nicotine 
conditions at that time point. 
 
Depressive symptoms. The hypothesis that relative to nicotine-containing conditions, 
non-nicotine-containing conditions would be associated with greater increases in CES-D scores 
over time among individuals with current MI relative to those without a diagnosis (H2) was not 
supported; the three-way interaction between current MI, time, and condition was not significant, 
F(4, 1336.49)=1.73, p=0.141.  
However, the interaction of time and condition was significant, F(4,1336.49)=1.729, 
p=0.049. Post hoc tests (see Figure 11) revealed significant between-group differences at week 4 
where participants randomized to non-nicotine conditions reported significantly greater CES-D 
scores (EMM=13.89, 95% CI =12.53,15.25) relative to participants randomized to the nicotine 






differences were observed within either condition grouping when comparing CES-D scores at 
week 0 to those reported at other time points (all ps>0.0125; Bonferroni adjusted).  
 
Figure 11. CES-D scores over time by condition grouping. CES-D=Center for Epidemiologic 
Studies Depression Scale. Analyses are unadjusted for covariates and represent estimated 
marginal means with 95% CI (lower limit, upper limit). One between-group comparison was 
done at each time point (no Bonferroni correction); asterisks (*) indicate a significant difference 
(p<0.05) between participants in the non-nicotine and nicotine conditions at that time point. No 
significant within-group differences were found (Bonferroni correction all ps>0.0125).  
 
For CES-D scores, no other two-way interactions were significant. However, the main 
effect of MI was significant, F(1, 521.27)=52.71, p<0.001. Across all time points, CES-D scores 
of smokers with MI were significantly higher (EMM=16.03, 95% CI=14.71,17.36) than the CES-
D scores of smokers without MI (EMM=9.90, 95% CI=8.90,10.90; p<0.001).  
Depressive symptoms: Sensitivity analysis. When controlling for demographics, site, 
CES-D scores at week 0, PSS score at week 0, other tobacco use, and PSCDI at week 0, as was 
observed in the adjusted model; the three-way interaction between current MI status, time, and 
condition was not significant, F(4,1306.64)=1.01, p=0.404.  
However, a significant interaction effect of time and current MI status was observed for 






CES-D scores of smokers without and with MI were observed at three time points. At week 8, 
smokers without MI reported significantly lower CES-D scores (EMM=11.14, 95% 
CI=10.08,12.20) than smokers with MI (EMM=12.97, 95% CI=11.56,14.37;  p=0.020). 
Similarly, significantly lower CES-D scores were reported at week 16 by smokers without MI  
(EMM=10.91, 95% CI=9.82,12.01) than by smokers with MI (EMM=14.28, 95% 
CI=12.80,15.76; p<0.001). Smokers without MI had significantly lower CES-D scores at week 
24 (EMM=10.46, 95% CI=9.36,11.56), relative to smokers with MI (EMM=13.52, 95% 
CI=12.04,14.99;  p<0.001). For the within-group post hoc tests, no significant differences in 




Figure 12. CES-D scores over time by condition grouping adjusted for covariates. CES-
D=Center for Epidemiologic Studies Depression Scale. Covariates included: sex, age, 
race/ethnicity, site, week 0 CES-D scores, week 0 perceived stress score, week 0 Penn State 
Cigarette Dependence Index score and other tobacco use. Estimated marginal means with 95% 
CI (lower limit, upper limit) are displayed. One between-group comparison was done at each 
time point (no Bonferroni correction); asterisks indicate a significant difference (p<0.05) 








Psychological distress. The hypothesis that relative to nicotine conditions, non-nicotine 
conditions would be associated with greater increases in Kessler-6 scores over time among 
individuals with current MI relative to those without current MI was not supported; the three-
way interaction between current MI status, time, and condition was not significant, 
F(4,1463.92)=1.96, p=0.099.  
No significant two-way interactions were observed for Kessler-6 scores including the 
interaction of time and condition, F(4,1463.92)=2.19, p=0.067; however, because this p-value 
was approaching significance, post hoc tests were conducted to explore between-group and 
within-group differences (see Figure 13). Post-hoc tests indicated significant differences between 
the nicotine and non-nicotine conditions at week 24, with smokers in the non-nicotine conditions 
reporting significantly greater Kessler-6 scores (EMM=5.81, 95% CI=5.09,6.53) relative to 
smokers in the nicotine conditions (EMM=4.48, 95% CI=3.72,5.23; p=0.012).  For within-group 
comparisons (using the same Bonferroni adjustment as previous models), no significant within-
group differences between Kessler-6 scores at week 0 and any other time points were observed 
for the non-nicotine condition (all ps>0.0125). Within the nicotine conditions, relative to 
Kessler-6 scores at week 0 (EMM=5.31, 95% CI=4.68,5.93), scores were significantly lower at 
week 4 (EMM=4.31, 95% CI=3.63,4.98], p=0.004) and week 8 (EMM=4.29, 95% CI=3.58,4.99; 








Figure 13. Kessler-6 scores over time by condition grouping. Analyses are unadjusted for 
covariates and represent estimated marginal means with 95% CI (lower limit, upper limit). One 
between-group comparison was done at each time point (no Bonferroni correction). Filled 
symbols indicate a significant difference relative to week 0 within that group (Bonferroni 
correction p<0.0125; four comparisons with week 0 were done for each group). Asterisks (*) 
indicate a significant difference (p<0.05) between participants in the non-nicotine and nicotine 
conditions at that time point. 
 
Of note, for Kessler-6 scores, there was a significant main effect of MI, 
F(1,532.79)=57.72, p<0.001. Smokers without MI had significantly lower Kessler-6 scores 
(EMM=3.60, 95% CI =3.17,4.04) than smokers with MI (EMM=6.36, 95% CI =5.76,6.93; 
p<0.001).  
Psychological distress: Sensitivity analysis. When controlling for demographics, site, 
Kessler-6 scores at week 0, PSS scores at week 0, other tobacco use, and PSCDI at week 0, as 
was observed in the unadjusted model, the three-way interaction of current MI status, time, and 
condition was not significant, F(4, 1443.01)=1.293, p=0.274.  
However, a significant interaction effect of time and current MI status on Kessler-6 
scores was observed, F(4,1443.19)=2.64, p=0.032. At week 0, smokers without MI had 






(EMM=5.39, 95% CI=4.71,6.07; p=0.024; see Figure 14). Similarly, significantly lower Kessler-
6 scores were observed at week 16 for smokers without MI (EMM=4.53, 95% CI=3.90,5.17) 
compared to smokers with MI (EMM=5.62, 95% CI=4.80,6.43; p=0.023). Also, smokers without 
MI had significantly lower Kessler-6 scores at week 24 (EMM=3.91, 95% CI=3.27,4.55) relative 
to smokers with MI (EMM=6.00, 95% CI=5.16,6.80; p<0.001). For the within-group 
comparisons relative to week 0, no significant differences in Kessler-6 scores were observed for 
other time points among smokers without or with MI (all ps>0.0125; Bonferroni adjusted).  
 
 
Figure 14. Kessler-6 scores over time by current MI status adjusted for covariates. Covariates 
include sex, age, race/ethnicity, site, week 0 Kessler-6 scores, week 0 perceived stress score, 
week 0 Penn State Cigarette Dependence Index score and other tobacco use. Estimated marginal 
means with 95% CI (lower limit, upper limit) are displayed. One between-group comparison was 
done at each time point (no Bonferroni correction); asterisks (*) indicate a significant difference 
(p<0.05) between participants in the non-nicotine and nicotine conditions at that time point. No 
significant within-group differences were found (Bonferroni correction all ps>0.0125).  
 
A significant main effect of condition was observed, F(1,503.15)=5.10, p=0.023. Post 






Kessler-6 scores (EMM=4.47, 95% CI =3.98,4.96) relative to smokers in the non-nicotine 
conditions (EMM=5.03, 95% CI =4.56,5.50; p<0.001).  
Perceived stress. The hypothesis that relative to nicotine conditions, non-nicotine 
conditions would be associated with greater increases in PSS scores over time among individuals 
with current MI relative to those without a diagnosis was not supported; the three-way 
interaction of current MI status, time, and condition was not significant, F(4,1455.20)=0.24, 
p=0.913.  
No significant two-way interactions were observed for PSS scores. There was, however, 
a significant main effect of MI on PSS scores, F(1,530.52)=16.84, p<0.001. Smokers with 
current MI reported significantly greater PSS scores (EMM=19.94, 95% CI =19.37,20.51) 
relative to smokers without MI (EMM=18.44, 95% CI=18.01,18.87, p<0.001).  A significant 
main effect of time on PSS scores was observed as well, F(4,1455.20)=10.66, p<0.001.  Relative 
to PSS scores at week 0 (EMM=20.08, 95% CI=19.65,20.52), PSS scores were significantly 
lower at week 4 (EMM=18.87, 95% CI=18.40,19.34), week 8 (EMM=19.27, 95% 
CI=18.77,19.76), week 16 (EMM=19.23, 95% CI=18.71,19.76), and week 24 (EMM=18.49, 
95% CI=17.97,19.02; all ps<0.0125, Bonferroni-adjusted).  
 
Perceived stress: Sensitivity analysis. When controlling for demographics, site, PSS 
scores at week 0, Kessler-6 scores at week 0, other tobacco use, and PSCDI at week 0, as was 
observed in the unadjusted model, the three-way interaction of current MI status, time, and 
condition was not significant,, F(4,1417.89)=0.613, p=0.653. No significant two-way 
interactions were observed for PSS. However, there was a significant main effect of time on PSS 






PSS scores were significantly lower at week 4 (EMM=18.36, 95% CI=17.82,18.90), week 8 
(EMM=18.63, 95% CI=18.06,19.20), week 16 (EMM=18.75, 95% CI=18.16,19.34), and week 
24 (EMM=18.13, 95% CI=17.55,18.72; all ps<0.0125, Bonferroni-adjusted).   
Aim 3 
For Aim 3, following z-score transformation of CES-D scores, Kessler-6 scores, and PSS 
scores, a composite index of “negative mood and stress” was created. A composite index of 
“negative mood” using only z-score transformed CES-D scores and Kessler-6 scores was also 
created. We tested these composite indices and individual negative mood and stress variables 
into our models as mediators of the relationship between condition (nicotine-containing vs. non-
nicotine-containing conditions) and CPD reduction over the course of the trial. The hypothesis 
that negative mood and stress measure measures would mediate condition effects on CPD 
reduction (H3a) was not supported for “negative mood and stress”, “negative mood”, depressive 
symptoms (as indexed by CES-D scores), psychological distress (as indexed by Kessler-6 
scores), or perceived stress (as indexed by PSS scores). 
Negative mood and stress. In the simple mediation model, condition was specified to 
have a direct effect on CPD reduction as well as an indirect effect through negative mood and 
stress indices using 5,000 bootstrap samples (see Figure 15). Please note all following path 
estimates are represented by b (b-weight). Neither the direct path from condition to negative 
mood and stress (b=-0.08, p=0.254) nor the direct path from negative mood and stress to CPD 
reduction was significant (b=-0.49, p=0.180). The direct path of condition to CPD reduction was 
significant (b=1.94, p=0.0014) with the nicotine-containing condition grouping being related to 
greater CPD reduction. The indirect effect of condition on CPD reduction through negative mood 










Figure 15. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples. Negative mood and stress= composite variable consisting of z-
transformed five-visit average CES-D scores, Kessler-6 scores, and PSS scores. a=direct path 
from condition to negative mood and stress; b=direct path from negative mood and stress to CPD 
reduction; c=direct path from condition to CPD reduction; c’=direct path from condition to CPD 
reduction controlling for negative mood and stress. Asterisks (*) indicate significance; ** 
(p<0.01). 
 
Negative mood and stress: Sensitivity analysis. We then entered demographics 
(race/ethnicity, age, and sex), site, and CPD at week 0 as covariates into each of the mediation 
models (see Figure 16). When controlling for the covariates, the direct path from condition to 
negative mood and stress was not significant (b=-0.08, p=0.294); however, the direct path from 
negative mood and stress to CPD reduction was significant (b=-0.73, p=0.0097) with greater 
negative mood and stress being related to smaller CPD reduction. The direct effect of condition 
on CPD reduction was significant (b=1.91, p<0.001), with the nicotine-containing condition 
grouping being related to greater CPD reduction. However, the indirect effect of condition on 






CI =-0.04,0.21), indicating that negative mood and stress neither partially nor fully mediated the 
relationship between condition and CPD reduction when controlling for covariates.  
 
Figure 16. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples and controlling for covariates. Negative mood and stress=composite 
variable consisting of z-transformed five-visit average CES-D scores, Kessler-6 scores and PSS 
scores. a=direct path from condition to negative mood and stress; b=direct path from negative 
mood and stress to CPD reduction; c=direct path from condition to CPD reduction; c’=direct 
path from condition to CPD reduction controlling for negative mood and stress. Asterisks (*) 
indicate significance; ** (p<0.01), *** (p<0.001).   
 
Negative mood. In the next mediation model, condition was specified to have a direct 
effect on CPD reduction as well as an indirect effect through negative mood indices alone using 
5,000 bootstrap samples (see Figure 17). Neither the direct path from condition to negative mood 
(b=-0.13, p=0.137) nor the direct path from negative mood to CPD reduction was significant 
(b=-0.41, p=0.195). The direct effect of condition on CPD reduction was significant (b=1.93, 
p=0.0015) with the nicotine-containing condition grouping being related to greater CPD 
reduction. The indirect effect of condition on CPD reduction through negative mood was not 
significant (b=0.05, 95% CI =-0.03,0.21), indicating that negative mood alone neither partially 







Figure 17. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples. Negative mood = composite variable consisting of z-transformed five-
visit average CES-D scores and Kessler-6 scores; a=direct path from condition to negative 
mood; b=direct path from negative mood to CPD reduction; c=direct path from condition to CPD 
reduction; c’=direct path from condition to CPD reduction controlling for negative mood. 
Asterisks (*) indicate significance; ** (p<0.01). 
 
Negative mood: Sensitivity analysis. While controlling for the same covariates as in 
previous models, condition was specified to have a direct effect on CPD reduction as well as an 
indirect effect through negative mood indices using 5,000 bootstrap samples (see Figure 18). The 
direct path from condition to negative mood was not significant (b=-0.13, p=0.139); however, 
the direct path from negative mood to CPD reduction was significant (b=-0.58, p=0.016) with 
greater negative mood being related to smaller CPD reduction. The direct effect of condition on 
CPD reduction was significant (b=1.90, p=0.0001) with the nicotine-containing condition 
grouping being related to greater CPD reduction. The indirect effect of condition on CPD 
reduction through negative mood was not statistically significant (b=0.07, 95% CI =-0.02,0.24), 
indicating that negative mood neither partially nor fully mediated the relationship between 







Figure 18. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples and controlling for covariates. Negative mood=composite variable 
consisting of z-transformed five-visit average CES-D scores and Kessler-6 scores; a=direct path 
from condition to negative mood; b=direct path from negative mood to CPD reduction; c=direct 
path from condition to CPD reduction; c’=direct path from condition to CPD reduction 
controlling for negative mood. Asterisks (*) indicate significance; * (p<0.05), *** (p<0.001).   
 
Depressive symptoms. Since none of the composite variables mediated the relationship 
between condition and CPD reduction, mean centered CES-D score was entered into the model 
as a mediator. In the simple mediation model, condition was specified to have a direct effect on 
CPD reduction as well as an indirect effect through CES-D scores using 5,000 bootstrap samples 
(see Figure 19). Neither the direct path from condition to CES-D scores (b=-1.0, p=0.212) nor 
the direct path from CES-D scores to CPD reduction was significant (b=-0.04, p=0.186). The 
direct effect of condition on CPD reduction was significant (b=1.93, p=0.0014) with the 
nicotine-containing condition grouping being related to greater CPD reduction. The indirect 
effect of condition on CPD reduction through CES-D scores was not statistically significant 
(b=0.04, 95% CI=-0.03,0.03), indicating that CES-D neither partially nor fully mediated the 







Figure 19. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples. Depressive symptoms=mean centered five-visit average CES-D scores; 
a=direct path from condition to depressive symptoms; b=direct path from depressive symptoms 
to CPD reduction; c=direct path from condition to CPD reduction; c’=direct path from condition 
to CPD reduction controlling for depressive symptoms. Asterisks (*) indicate significance; ** 
(p<0.01).  
 
Depressive symptoms: Sensitivity analysis. While controlling for covariates, the mean 
transformed variable CES-D was then entered into the model as a mediator. In the mediation 
model, condition was specified to have a direct effect on CPD reduction as well as an indirect 
effect through CES-D using 5,000 bootstrap samples (see Figure 20). The direct path from 
condition to CES-D scores was not significant (b=-0.99, p=0.219). The direct path from CES-D 
scores to CPD reduction was significant (b=-0.06, p=0.023) with greater CES-D scores being 
related to smaller CPD reduction. The direct effect of condition on CPD reduction was 
significant (b=1.91, p<0.001) with the nicotine-containing condition grouping being related to 
greater CPD reduction. The indirect effect of condition on CPD reduction through CES-D scores 
was not significant (b=0.06, 95% CI=-0.03,0.21), indicating that CES-D neither partially nor 









Figure 20. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples and controlling for covariates. Depressive symptoms=mean centered 
five-visit average CES-D scores; a=direct path from condition to depressive symptoms; b=direct 
path from depressive symptoms to CPD reduction; c=direct path from condition to CPD 
reduction; c’=direct path from condition to CPD reduction controlling for depressive symptoms. 
Asterisks (*) indicate significance; * (p<0.05), *** (p<0.001).   
 
Psychological distress. In the next mediation model, condition was specified to have a 
direct effect on CPD reduction as well as an indirect effect through Kessler-6 scores using 5,000 
bootstrap samples (see Figure 21). Neither the direct path from condition to Kessler-6 scores 
(b=-0.56, p=0.101) nor the path from Kessler-6 scores to CPD reduction (b=-0.09, p=0.234) was 
significant. The direct path from condition to CPD reduction was significant (b=1.93, p=0.0015), 
with the nicotine-containing condition grouping being related to greater CPD reduction. The 
indirect effect of condition on CPD reduction through Kessler-6 scores was not significant 
(b=0.05, 95% CI =-0.03,0.22), indicating that Kessler-6 scores neither partially nor fully 







Figure 21. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples. Psychological distress=mean centered five-visit average Kessler-6 
scores; a=direct path from condition to psychological distress; b=direct path from psychological 
distress to CPD reduction; c=direct path from condition to CPD reduction; c’=direct path from 
condition to CPD reduction controlling for psychological distress. Asterisks (*) indicate 
significance; ** (p<0.01).   
 
 Psychological distress: sensitivity analysis. While controlling for covariates, the z-
transformed variable Kessler-6 was then entered into the model as a mediator. In the mediation 
model, condition was specified to have a direct effect on CPD reduction as well as an indirect 
effect through Kessler-6 using 5,000 bootstrap samples (see Figure 22). The direct path from 
condition to Kessler-6 scores was not significant (b=-0.56, p=0.1004). The direct path from 
Kessler-6 scores to CPD reduction was significant (b=-0.14, p=0.0169) with greater negative 
mood and stress being related to smaller CPD reduction. The direct effect of condition on CPD 
reduction was significant (b=1.89, p=0.0001) with the nicotine-containing condition grouping 
being related to greater CPD reduction. The indirect effect of condition on CPD reduction 
through Kessler-6 scores was not statistically significant (b=0.08, 95% CI =-0.01,0.25), 
indicating that Kessler-6 scores neither partially nor fully mediated the relationship between 







Figure 22. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples and controlling for covariates. Psychological distress=mean centered 
five-visit average Kessler-6 scores; a=direct path from condition to psychological distress; 
b=direct path from psychological distress to CPD reduction; c=direct path from condition to 
CPD reduction; c’=direct path from condition to CPD reduction controlling for psychological 
distress. Asterisks (*) indicate significance; * (p<0.05), *** (p<0.001).   
 
Perceived stress. We then entered the mean centered variable PSS into the model as a 
mediator. In the simple mediation model, condition was specified to have a direct effect on CPD 
reduction as well as an indirect effect through PSS scores using 5,000 bootstrap samples (see 
Figure 23). Neither the direct path from condition to PSS scores (b=0.01, p=0.965) nor the direct 
path from PSS scores to CPD reduction (b=-0.07, p=0.408) was significant. The direct effect of 
condition onto CPD reduction was significant (b=1.98, p=0.0011) with the nicotine-containing 
condition grouping being related to greater CPD reduction. The indirect effect of condition on 
CPD reduction through PSS scores was not significant (b=-0.001, 95% CI =-0.07,0.09). These 
results indicate that PSS scores neither partially nor fully mediated the relationship between 







Figure 23. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples. Perceived stress=mean centered five-visit average PSS scores; a=direct 
path from condition to perceived stress; b=direct path from psychological distress to CPD 
reduction; c=direct path from condition to CPD reduction; c’=direct path from condition to CPD 
reduction controlling for perceived stress. Asterisks (*) indicate significance; ** (p<0.01). 
 
Perceived stress: Sensitivity analysis. While controlling for covariates, the mean 
centered variable PSS was then entered into the model as a mediator. In the mediation model, 
condition was specified to have a direct effect on CPD reduction as well as an indirect effect 
through PSS scores using 5,000 bootstrap samples (see Figure 24). In this model, neither the 
direct path from condition to PSS scores (b=0.08, p=0.789), nor the direct path from PSS to CPD 
reduction was significant (b=-0.12, p=0.074). The direct effect of condition on CPD reduction 
was significant (b=1.98, p<0.0001), with the nicotine-containing condition being related to 
greater CPD reduction. The indirect effect of condition on CPD reduction through PSS scores 
was not statistically significant (b=-0.01, 95% CI=-0.10,0.08), indicating that PSS scores neither 
partially nor fully mediated the relationship between condition and CPD reduction when 







Figure 24. Simple mediation model with unstandardized path loadings and standard errors using 
5,000 bootstrap samples and controlling for covariates. Perceived stress=mean centered five-visit 
average PSS scores; a=direct path from condition to perceived stress; b=direct path from  
perceived stress to CPD reduction; c=direct path from condition to CPD reduction; c’=direct path 
from condition to CPD reduction controlling for perceived stress. Asterisks (*) indicate 
significance; *** (p<0.001).   
 
We had initially hypothesized (H3b) that the mediation effect of “negative mood and 
stress” would be stronger among individuals with current MI; however, because none of the 
mediation models were significant, no moderated mediation models were conducted.  
Discussion 
In order to inform harm mitigation efforts for a vulnerable population of smokers, the 
present study aimed to investigate whether nicotine-containing ENDS as compared to non-
nicotine-containing products produced differential effects on CPD reduction and changes in 
negative mood and stress indices for smokers without and with current MI (Aim 1 and 2). 
Related to these aims, the present study also investigated how negative mood and stress 
measures may influence the effects of ENDS on CPD reduction and whether these effects 
differed by current MI status (Aim 3). A summary and interpretation of our findings by each aim 






Aim 1: Cigarettes per day 
The hypothesis that smokers with current MI would report smaller CPD reduction over 
24 weeks than their counterparts without current MI (H1a) was partially supported. Participants 
without and with MI significantly decreased their CPD over time but smokers with current MI 
did not reduce their CPD to the same extent as those without MI at week 16 and week 24. These 
differences by MI status were observed prior to including relevant covariates as controls. Of 
note, the similarity in CPD between participants with and without MI at baseline (week 0) was 
surprising as smokers with MI tend to smoke more cigarettes relative to smokers without MI 
(Fergusson et al., 2003; Greenberg et al., 2012). However, effects noted at the later study time 
points indicated that smokers with current MI had a more difficult time reducing their CPD as 
the study went on (at least prior to covariate adjustment).  
The latter finding may be related to the prevalence of depression and anxiety in our MI 
sample, with over 20% of participants reporting at least one of the two conditions. Past literature 
highlights that smokers with depression experience a more difficult time quitting than smokers 
without depression (Glassman et al., 1990). The differences observed at later time points in the 
primary analysis also may represent evidence that smokers with MI use cigarette-delivered 
nicotine to alleviate MI-related symptoms (Goldstein, 1987). For example, nicotine 
administration has been found to decrease anxiety (Pomerleau et al., 1984) and depressive 
symptoms (Haro & Drucker-Colin, 2004a). If cigarettes were used to assist with MI symptom 
management, smokers with current MI may have been reluctant to decrease their smoking past a 
certain threshold which provided symptom relief regardless of their study product’s nicotine 
content. Of note, smokers with depressive symptoms experience greater nicotine abstinence 






Ledgerwood, 2016). Differences in the severity of nicotine abstinence-related symptoms also 
may help explain why those with MI had more difficulty reducing their CPD at the last two time 
points. Brief measures of nicotine abstinence symptoms were assessed during the current study 
(see Lopez et al., 2016) and could be incorporated into future analyses to understand their 
relationship to cigarette smoking behavior. However, we did observe the loss of these significant 
differences by current MI status for CPD after controlling for covariates. The covariates which 
were significant in this model included race/ethnicity, site, and CPD at week 0 (see Table 11). 
These associations suggest an overlap of these factors with current MI status which is consistent 
with the associations observed at the bivariate level for race/ethnicity and site (see Table 8).   
 Patterns of CPD reduction by condition grouping observed in this study support the idea 
that ENDS that deliver nicotine are more effective in reducing smoking behavior as compared to 
a non-nicotine ENDS and/or CIG SUB. Our findings are consistent with the parent study (Cobb 
et al., 2021). However, the parent study did not collapse conditions, and significant differences in 
CPD were identified between CIG SUB and the 0, 8 and 36 mg/ml ENDS conditions. It is likely 
that the differences by condition grouping were driven by the effects previously described by 
Cobb et al. (2021). These findings also correspond to the acute clinical laboratory study (Hiler et 
al., 2017) that utilized the same ENDS and liquid solution among smokers. Here the nicotine-
containing ENDS conditions resulted in cigarette-like and less than cigarette-like nicotine 
delivery (see Table 1), and nicotine-containing ENDS resulted in more effective suppression of 
nicotine abstinence symptoms as compared to 0 mg/ml ENDS. These attributes (among others) 
may help explain why those assigned to the nicotine-containing ENDS reduced their smoking 






Regardless of whether we controlled for additional variables or not, the hypothesis that 
between-condition differences in CPD reduction as produced by condition grouping would differ 
as a function of current MI status was not supported (H1b). Differences in smoking behavior by 
current MI status and condition grouping over time were too small and/or too variable to be 
detected. One interpretation of this finding is that current MI status did not interfere with 
condition-related effects. ENDS with nicotine were effective in smokers with and without MI 
and non-nicotine conditions did not result in discrepant patterns of CPD reduction between these 
two groups. Our examination of the two-way interactions observed are consistent with this 
interpretation, but there are other features of our analysis that may have influenced our ability to 
detect effects by condition and MI status.  
By grouping conditions by nicotine content, rather than comparing the four unique 
randomized conditions, we may have diluted some effects that may have otherwise been 
observed. The parent study results (Cobb et al., 2021) revealed that only the 36 mg/ml condition 
resulted in significant reductions in smoking behavior and the urinary carcinogen biomarker 
(versus reductions in smoking behavior alone). The 36 mg/ml condition also resulted in the 
greatest smoking reduction although levels were not significantly different compared to the other 
ENDS conditions (0 mg/ml and 8 mg/ml).  While adding statistical power, collapsing the 36 
mg/ml and 8 mg/ml conditions may have made it more difficult to discern differences by 
nicotine content status. Of note, a lack of significant differences between nicotine and non-
nicotine containing ENDS has been observed in other clinical trials for cigarette smoking 
abstinence outcomes (Bullen et al., 2013; Eisenberg et al., 2020). For example, in a yearlong 
double-blind RCT among smokers not interested in quitting, no significant differences were 






mg/ml ENDS conditions, although all conditions resulted in significant decreases in CPD 
(Caponnetto et al., 2013).  
 Another contributing factor to our ability to detect differences by MI status may have 
been our approach to defining current MI. MI diagnoses are warranted if the participant’s daily 
functioning is strongly and negatively impacted (APA, 2013). However, when symptoms are 
alleviated and functioning is restored through pharmaceutical and/or behavioral treatment, a 
smoker’s MI, although a valid and current diagnosis, may no longer impact smoking-related 
behavior to the same degree as the MI of an individual with uncontrolled MI symptoms. Current 
MI, as defined in this study, did not indicate presence and/or severity of MI-related functional 
impairment and may therefore have omitted differences in the severity of MI that may have 
confounded our estimates of interest. The lack of assessment of current MI-related functional 
impairment also may help explain why no significant differences in baseline CPD were observed 
between smokers without and with current MI unlike previous work (e.g., Greenberg et al., 
2012). Another explanation for the lack of interaction between current MI and condition may be 
that participants with current MI simply did not experience as many difficulties when assigned to 
non-nicotine conditions as we had hypothesized. Future work using data from this RCT could 
probe study product use behavior and acceptibility-related measures of ENDS conditions by 
current MI status to better understand these effects.  
As noted in the methods section, we had sufficiently high power to detect main effects of 
condition and MI status, but rather low power to detect interactions between those two factors. 
Future research efforts should consider categorizing MI not based on a self-reported diagnosis 
through a medical professional, but instead based on symptom prevalence assessed by a 






identify a range of MI; for example, the Mini-International Neuropsychiatric Interview (MINI) 
presents a brief structured interview that can be effectively used in epidemiological research and 
multicenter clinical studies (Sheehan et al., 1998). The MINI measures MI that were assessed via 
self-reported medical diagnoses in the parent study as well as several other MI and has been 
found to have high sensitivity and specificity (Sheehan et al., 1998). Identifying MI symptom 
prevalence and severity would have allowed us to categorize those with current symptoms 
(instead of a current diagnosis alone) as experiencing current MI-related distress. Those with 
current symptoms would likely be most vulnerable to condition grouping-related presence or 
absence of nicotine.  
Another approach that future trials could use would be to focus recruitment among 
individuals with current MI which has already been done for clinical trials of reduced nicotine 
content cigarettes which limited recruitment to smokers with affective disorders or substance use 
disorders (Higgins et al., 2020). Including only individuals with MI would increase statistical 
power while simultaneously allowing for some comparisons across MI status (e.g., lifetime MI 
vs. current MI). Doing so would allow for identification of potential subgroups with enhanced 
MI-related vulnerability for worse outcomes. To address the next aim, we investigated the 
influence of current MI status and condition on indices of depressive symptoms, psychological 
distress, and perceived stress.  
Aim 2. Negative mood and stress 
Our hypothesis that relative to the nicotine conditions, the non-nicotine conditions would 
be linked to greater increases in negative mood and stress measures among individuals with 






on the negative mood measures first and then on perceived stress. Only in the unadjusted models, 
depressive symptoms and psychological distress scores differed by condition grouping and time 
with significantly lower scores noted for the nicotine conditions compared to the non-nicotine 
conditions. When adjusting for covariates, these condition grouping-related effects were less 
apparent but differences by current MI status over time were noted with significantly greater 
depressive symptoms and psychological distress scores at later time points for those with current 
MI.  
While condition grouping-related effects on negative mood were only present in 
unadjusted analyses, these findings highlight the ability of nicotine-containing ENDS to alleviate 
symptoms of negative affect during smoking reduction in a setting outside the clinical lab. These 
findings are also in line with past research that suggests tobacco users experience negative 
psychological symptoms when abstaining from nicotine, including restlessness, nervousness, 
anxiety, irritability and sadness (Hughes & Hatsukami, 1986; Post et al., 2010). Based on the 
parent study results (Cobb et al., 2021) and the associated acute clinical lab study (Hiler et al., 
2017) participants randomized to the 36 mg/ml condition were likely able to more effectively 
suppress their nicotine abstinence-associated symptoms (Hiler et al., 2017) including negative 
mood.  
Depressive symptoms did not change over time, but psychological distress for the 
nicotine-containing conditions decreased significantly at weeks 4 and 8 compared to baseline 
(week 0). Perhaps not collapsing the conditions by nicotine content would have allowed us to 
isolate a more pronounced condition-related effect in regards to negative mood and stress. While 
the parent study analyses did not investigate negative mood among participants, significant 






reduction (Cobb et al., 2021). These CPD-related findings highlight the need to differentiate 
between the CIG SUB and ENDS with 0 mg/ml. For example, CIG SUB was the least effective 
of all four study products in regards to CPD reduction (Cobb et al., 2021), and past research 
suggests that a 0 mg/ml ENDS can suppress some nicotine abstinence symptoms (Caponneto et 
al., 2012; Hiler et al., 2017). The CIG SUB and 0 mg/ml ENDS condition may have differed in 
terms of their effects on negative mood. However, the presence and/or lack of these condition-
related effects should be interpreted with caution given that after controlling for covariates, the 
interaction of time and condition was no longer significant for neither depressive symptoms nor 
psychological distress. When considering the covariate associations observed in these models 
(see Table 11), baseline levels of negative mood and stress may have contributed to the 
condition-related effects observed. 
After adjusting for covariates, the significant interaction of MI and time revealed that 
individuals with current MI had significantly higher depressive symptoms and psychological 
distress at later study time points compared to those without current MI. For psychological 
distress only, baseline scores also were significantly elevated for those with current MI. The 
observation that participants with current MI reported significantly greater negative mood at 
several time points throughout the study is not surprising. Depression was the most frequently 
reported MI in our sample and it is expected that individuals suffering from depression would 
score higher on the CES-D given the measure’s purpose. Moreover, nonspecific psychological 
distress is related to affective distress (Dohrenwend et al., 1980), and the majority of our 
participants with current MI reported depression and anxiety, i.e., affective disorders. While 
nonspecific psychological distress is not linked to any single specific MI (Dohrenwend et al., 






for an MI (Lawrence et al., 2011). Of note, there were no significant changes in negative mood 
measures over time for adjusted analyses.  
Our hypothesis that relative to the nicotine condition grouping, the non-nicotine condition 
grouping would be linked to greater increases in negative mood and stress among individuals 
with current MI relative to those without (H2) was not supported for perceived stress. There were 
no significant two-way interactions either prior to or after controlling for covariates. Some 
fundamental differences between the negative mood measures and the perceived stress measure 
may explain the absence of two-way interactions previously identified for the negative mood 
measures. The CES-D has been designed to assess current depressive symptoms (Radloff, 1997). 
The Kessler-6 assesses psychological distress (a construct while not indicative of any specific 
MI) that related to affective distress (Dohrenwend et al., 1980). Psychological distress is usually 
high among individuals who meet the diagnostic criteria for an MI (Lawrence et al., 2011). 
While the PSS has also been found to correlate highly with depressive symptoms, the PSS 
measures an independent and different construct (Cohen, 1983). Past research (not among 
smokers specifically) has highlighted that individuals with MI report increased perceived stress 
due to the MI-related stigma they experience (Rüsch et al., 2009) and are more likely to report 
stressful life events (Silver et al., 2005). The high prevalence of perceived stress and objective 
stressors among individuals with MI may help explain the main effect of MI observed for 
perceived stress. However, after controlling for covariates, we were no longer able to identify 
any significant differences in perceived stress between participants with and without current MI. 
Covariate associations identified during the sensitivity analyses suggest potential overlap of the 
current MI construct with demographics and baseline perceived stress and psychological distress 






Unlike the main effects of MI for perceived stress, significant declines for PSS relative to 
baseline were observed in the unadjusted and adjusted analysis. There was no differential effect 
of condition grouping that may have explained this decrease in perceived stress over time, which 
is in disagreement with some literature highlighting that smoking serves as a stress management 
tool (e.g., McEwen et al., 2008). The role of smoking as an effective stress management tool for 
smokers is disputed; some research indicates that smoking may actually exacerbate negative 
emotions long-term but that stopping smoking is followed by a reduction of perceived stress 
(Hajek et al., 2010). Perhaps the significant decreases in perceived stress over time occurred due 
to the study-related CPD reduction which was present in all conditions.  
Surprisingly, no condition-related effects on perceived stress were observed either before 
or after covariate adjustment. When placing the findings associated with negative mood and 
stress into context, the bidirectional relationship of negative mood and stress with smoking 
should be considered. While the self-medication hypothesis assumes the antecedence of 
symptoms of an MI followed by nicotine self-administration to alleviate those symptoms 
(Goldstein, 1987), some research suggests that smoking can also occur first and subsequently be 
followed by an onset of depression later on (Breslau et al., 1998). Similarly, daily smoking has 
been linked to panic attacks at a later time point without panic attacks predicting initiation of 
smoking later on (Breslau & Klein, 1999). Through a bidirectional lens, the lack of nicotine in 
the non-nicotine conditions may not have had an exacerbating effect on symptoms of negative 
mood and stress for individuals with MI. In fact, reducing nicotine intake may have positively 
impacted MI-related symptoms. Past research has established that smokers who quit successfully 
reported significantly fewer days on which they experienced depressive symptoms relative to 






not a smoking cessation study, perhaps successful reduction of CPD in accordance with the 
researchers’ instructions was sufficient to affect negative mood and stress positively. However, 
the same factors previously implicated in Aim 1 results may have prevented our ability to detect 
these effects including current MI categorization method. Since we did not assess MI-related 
functional impairment among our participants, we cannot be certain that they exhibited 
sensitivity to the absence of nicotine to the degree individuals with MI-related functional 
impairment might experience. Among individuals reporting current MI, only 39.2% of met the 
clinical cutoff for the CES-D and only 14.9% met the clinical cutoff for the Kessler-6; therefore, 
effects may have been not pronounced enough to be detected. Past research supports this 
possibility. For example, baseline depressive symptoms have been highlighted as critical to how 
smokers respond to a decrease in nicotine in the past. Findings from a cessation study suggest 
that while participants with high baseline depressive symptoms experienced an increase of 
withdrawal symptoms in the first week, participants with low baseline depressive symptoms 
experienced a decrease in withdrawal symptoms in the first week (Reid & Ledgerwood, 2016). 
One particular aspect of the present analysis that could be addressed in future research is 
the more frequent monitoring of negative mood and stress symptoms. In addition, the Kessler-6 
and the PSS assess experiences from the past month versus a more immediate time period. Use 
of this timeframe may have omitted experiences and symptoms that occurred early in the month 
or recall error may have impacted those that were less frequent overall. Administering negative 
mood and stress measures more frequently throughout a longitudinal study may allow 
researchers to isolate the timeframe after initial smoking reduction when such symptoms may be 
most pronounced. For example, an ideal design might incorporate past week mood measures or 






While we did not identify an interaction between current MI status and condition on negative 
mood and stress measures, future work that assesses these measures over shorter time intervals 
may help to isolate factors contributing to the changes in negative mood and stress we observed.   
Aim 3. Relationship between condition, CPD reduction, and negative mood and stress  
The hypothesis that changes in negative mood and stress would mediate condition effects 
on CPD reduction was not supported when using the composite variable of depressive 
symptoms, psychological distress, and perceived stress, the composite variable of depressive 
symptoms and psychological distress, or depressive symptoms, psychological distress, and 
perceived stress individually as mediators either prior to or after controlling for covariates. 
Condition did not serve as a significant predictor of any of the five mediators tested prior to and 
after controlling for covariates. None of the five mediators significantly predicted CPD reduction 
prior to controlling for covariates. However, after controlling for covariates, both composite 
variables and the individual variables, depressive symptoms and psychological distress, 
significantly predicted CPD reduction, with greater negative mood and stress being related to 
smaller CPD reduction. Perceived stress alone did not predict CPD reduction. In addition, prior 
to as well as after controlling for covariates, condition served as a significant predictor of CPD 
reduction, with the nicotine-containing conditions being linked to greater CPD reduction. The 
lack of significant direct effects of condition for all mediators tested in Aim 3 mostly aligned 
with our findings from Aim 2. In Aim 2, there was little evidence of condition-related effects 
over time for measures of negative mood and stress with the exception of the CES-D in the 
unadjusted model. Some of these minor differences in condition-related findings between Aim 2 
and Aim 3 are likely due to the time points being assessed; while Aim 2 assessed trajectory over 






0) and week 24. The direct effects of condition on CPD reduction in Aim 3 also were consistent 
with patterns observed in Aim 1.  
The finding that changes in negative mood and stress were not predicted by condition is 
surprising because past research suggests that smokers’ feelings of stress are influenced by 
nicotine administration, with greater stress levels being reported prior to smoking than after 
smoking (Parrott, 1994a; Parrott, 1994b). Importantly, nicotine-deprived smokers experience 
significantly greater depressive symptoms, irritability, and concentration difficulties as well as 
significantly lower pleasure relative to non-nicotine-deprived smokers and nonsmokers (Parrott, 
1994b). These differences indicate that smoking may not in fact facilitate positive mood but 
merely produce alleviation of negative mood pre-smoking resulting from nicotine deprivation 
(Parrott, 1994b). Since baseline nicotine dependence did not differ significantly between the non-
nicotine condition grouping and the nicotine condition grouping, we expected that the presence 
or absence of nicotine in the study product assigned would have been related to negative mood 
and stress symptoms. Instead, our findings suggest that condition-related effects did not result in 
differential patterns of negative mood and stress symptoms that in turn influenced CPD 
reduction. Perhaps, not observing a relationship between condition and negative mood and stress 
may indicate that smokers, including smokers with MI, may not be as sensitive to a study 
product-related nicotine content as we had hypothesized. In turn, these results would indicate 
that ENDS, should they be deemed an effective and safe smoking reduction and cessation tool, 
may not exacerbate the risk of negative mood and stress symptoms.  
A possible reason for the lack of direct condition-related effects on measures of negative 
mood and stress was how these mediators were calculated. The present study assessed five visits 






observed in the unadjusted analyses, CES-D scores diverged between non-nicotine and nicotine 
conditions early on in the intervention (week 4; see Figure 11), but these differences dissipated 
as time went on.  Also observed in the unadjusted analyses, Kessler-6 scores diverged between 
non-nicotine and nicotine conditions at later study time points (week 24; see Figure 13). Our 
mediation analyses could have been structured to examine relationships between these variables 
at early versus later time points. Some research suggests that nicotine withdrawal symptoms 
subside within as little as ten days (Shiffman et al., 2006). Assessing a time span of 24 weeks, 
however, may have diluted early effects of condition-related nicotine content on negative mood 
and stress as participants in the non-nicotine containing condition may have adapted to their 
decreased nicotine intake. Also, because of the timeframe assessed by the measures used (i.e., 
past week and past month), critical time points during which changes in negative mood and 
stress may have occurred were not captured. Timeframe differences assessed via negative mood 
measures may have contributed to discrepancies observed in results from Aims 2 and 3.   
Negative mood and stress symptoms significantly predicted CPD reduction after 
adjusting for covariates. This difference suggests that the included covariates improved our 
ability to detect this effect in our model. These findings are in line with past research. For 
example, smokers suffering from psychological distress smoke more CPD relative to smokers 
not suffering from psychological distress (Kulik & Glantz, 2017), and negative affect is linked to 
increased smoking urges (Brodbeck et al., 2014). Depressive symptoms are related to poorer 
cessation outcomes (Leventhal et al., 2008), and negative mood leads to increased relapse risk 
(Tulloch et al., 2016). Interestingly, even after controlling for covariates, perceived stress did not 
predict CPD reduction. Given that increased perceived stress is linked to cessation difficulties 






would have predicted CPD reduction, with those reporting greater perceived stress experiencing 
greater smoking reduction difficulties. One possible explanation as to why perceived stress was 
not a significant predictor of CPD reduction is that across our entire sample, only 3.8% reported 
severe perceived stress at baseline and mild or moderate levels of perceived stress may not have 
influenced smoking behaviors sufficiently to detect an effect. Another explanation is that 
smokers may have either managed or altogether avoided increases in perceived stress by altering 
their smoking behavior which would explain why such increases were not detected by our 
analysis. Importantly, prior to and after sensitivity analyses, condition significantly predicted 
CPD reduction, which is consistent with Aim 1 results as well as the parent study (Cobb et al., 
2021). The finding that negative mood and stress did not serve as mediators raises the question 
of what psychological variables, if any, may help explain the relationship between ENDS-
delivered nicotine and the absence thereof on smoking reduction. The investigation of such 
variables is critical particularly for smokers with MI as past research has shown that negative 
mood and stress are prevalent among this group (Lawrence et al., 2011; Rüsch et al., 2009).  
Effective mood management is a critical factor in ensuring success in smoking reduction 
and cessation efforts among smokers with MI. More research is needed to evaluate the 
effectiveness of ENDS on smoking reduction and cessation among this vulnerable group. 
However, our findings highlight that ENDS-supported reduction among smokers with MI could 
perhaps be improved by integrating a behavioral treatment component to avoid the interference 
of negative mood symptoms with reduction or cessation outcomes. Future research should 
evaluate whether a cognitive behavioral therapy component added to ENDS-supported smoking 
reduction may help offset the detrimental effect of negative mood on successful reduction or 






stress or other, unassessed psychological variables on the relationship between condition and 
CPD reduction would have differed by current MI status. Future research should investigate 
how, if at all, smokers with MI may exhibit worsening or improvement of psychological 
variables when undergoing ENDS-supported smoking reduction or cessation, as our findings 
suggested no interaction effect of current MI and condition on negative mood and stress or CPD 
reduction. Results derived from such research would provide valuable information on the 
potential effectiveness of ENDS as smoking reduction and cessation tool among this vulnerable 
population. Future work that leverages the lessons learned from this study is needed.  
Limitations 
 Several limitations of the present analyses must be considered. Despite collapsing 
conditions by condition-related nicotine content, our three-way interactions corresponding with 
our hypotheses likely still were underpowered. We also had a substantial amount of missing data 
(~40% dropped out by the last study visit). While we applied REML and EM to address this 
issue, using estimated data presents a limitation, particularly considering that we used intent to 
treat and did not exclude those with larger amounts of missing data. Estimates based on 
participants who missed several visits may be less accurate than imputed data for participants 
who only missed one visit. A supplemental sensitivity analysis used by Cobb et al. (2021) which 
includes only individuals who had attended visits and provided data at relevant time points may 
be warranted (i.e., “per-protocol”). Such sensitivity analyses also could include the covariates 
that were associated with dropout (e.g., age at smoking initiation and education). However, all of 
the results including those with complex multiple imputation and per-protocol presented in Cobb 






(as in this study) in regards to CPD. We may not find differential effects for the present results 
by conducting these sensitivity analyses.  
As described above, our categorization of MI was likely flawed. Participants who 
reported that the condition was ongoing may have done so because they continue to receive 
cognitive behavioral therapy and/or medical treatment for their condition. However, the 
symptoms of their MI may have been well controlled due to the effects of medication and/or 
behavioral treatment. In turn, those who reported no ongoing MI may have done so not due to an 
absence of symptoms but because they assumed their MI to be resolved.  By grouping all current 
MI, our analysis also did not take into consideration between-group differences in smoking 
intensity and/or nicotine dependence that present among individuals suffering from different MI. 
For example, participants suffering from schizophrenia and bipolar disorder have the highest 
smoking rates among individuals with MI (McClave et al., 2010), even exceeding rates found 
among individuals with depression and anxiety (ADAA, 2018; SAMSHA, 2019). Smokers with 
greater MI functional impairment and/or more severe MI likely did not participate in this study 
due to exclusion criteria (uncontrolled mental illness or substance abuse including in-patient 
treatment within the past six months) and/or the design itself (i.e., number of visits and the use of 
a potentially unfamiliar study product). Moreover, participants may not have been adequately 
categorized by self-reported MI status if they lacked access to healthcare or lacked awareness of 
MI and their presenting symptoms. Similarly, because the data included in the present study 
stemmed from five in-person visits stretching across 24 weeks, it is possible that individuals 
were diagnosed with a new MI during this time or experienced an acute onset of a previously 






of current MI may have omitted between-group differences that likely would have contributed to 
differences in our outcomes.  
Another limitation is due to the possible influence of unassessed variables on CPD 
changes over time. Of note, while participant use of their assigned study product use was 
assessed, it was not always objectively verified, and participants were not penalized for non-
compliance (Cobb et al., 2021). Changes observed in CPD may not be due solely due to 
condition assignment but also how individuals used their study product and whether they used 
non-study products to self-administer nicotine. Additionally, two variables that have been 
identified by past research as influential on smoking cessation were not assessed during the time 
points on which we focused our analyses. For example, self-efficacy, the belief in one’s personal 
ability to complete actions necessary to reach a goal (Bandura, 1982) has been identified as a 
significant predictor of smoking cessation (e.g., Stuart et al., 1994). Smokers who maintain long-
term smoking abstinence had significantly higher self-efficacy than smokers who relapsed 
(DiClemente, 1981). In addition, readiness to change, i.e., motivation (DiClemente & Prochaska, 
1985), has been identified as a significant predictor of smoking cessation; individuals classified 
as being in a higher stage of change made increased quit attempts and were significantly more 
likely to abstain from smoking relative to their counterparts in lower stages of change 
(DiClemente et al., 1991). While participants in our study reported no interest in smoking 
cessation at screening, some research suggests that readiness and confidence to quit smoking 
may have developed during the intervention period. For example, past research involving a 
sample of smokers who were naive to ENDS and were not interested in quitting, found that after 
participation in an experimental in-lab phase and a subsequent ad lib phase using ENDS, 






al., 2014). Inclusion of these variables at different time points throughout the study could have 
allowed us to identify an additional critical factor to help explain our findings.  
Conclusions 
Smokers with MI are at a heightened risk for smoking-related health consequences. 
ENDS present a possible harm reduction tool for this vulnerable group given their ability to 
deliver nicotine and their reduced toxicant exposure compared to cigarette smoking. We found 
some evidence that smokers with MI may experience greater difficulties reducing CPD; 
however, this effect diminished after controlling for relevant covariates. Overall, condition-
related effects did not differ significantly by current MI status meaning that the enhanced ability 
of the nicotine conditions (ENDS with 8 mg/ml and 36 mg/ml) compared to the non-nicotine 
conditions (CIG SUB and ENDS with 0 mg/ml) to reduce smoking behavior was not dampened 
among smokers with MI. There was some evidence that during the intervention smokers with MI 
experienced higher levels of negative mood and stress, but changes in negative mood and stress 
did not explain the relationship between condition and CPD reduction. This latter finding 
suggests that these psychological indices may not be the mechanism by which the nicotine 
conditions promoted smoking reduction. Future work may benefit from examination of other 
mood-related indices possibly more closely tied to nicotine withdrawal and dependence in 
relationship to MI status. The overall effect of negative mood on changes in smoking behavior 
reinforces intervention efforts that incorporate cognitive behavioral therapy or some other 
treatment modality that targets mood to improve smoking reduction and/or cessation outcomes. 
Use of better MI assessments and related measures when testing the effects of ENDS is also 
needed to deepen our understanding of this product class among smokers with MI.  Importantly, 






for smokers with MI in our study. Taken together, the results of this study indicate that ENDS 
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